[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23498
1. Parihar A, Parihar MS, Nazarewicz R, Ghafourifar P: Importance of cytochrome c redox state for ceramide-induced apoptosis of human mammary adenocarcinoma cells. Biochim Biophys Acta; 2010 Jul;1800(7):646-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of cytochrome c redox state for ceramide-induced apoptosis of human mammary adenocarcinoma cells.
  • The present study delineates importance of the redox state of cytochrome c for release of cytochrome c and apoptosis of human mammary adenocarcinoma MCF-7 and MDA-MB-231 cells induced by ceramides.
  • CONCLUSIONS: Ceramides induce oxidative stress and apoptosis in human mammary adenocarcinoma cells by interacting with oxidized cytochrome c leading to the release of cytochrome c from the mitochondria.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / drug effects. Breast Neoplasms / pathology. Ceramides / pharmacology. Cytochromes c / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20382204.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ceramides; 9007-43-6 / Cytochromes c; GAN16C9B8O / Glutathione
  •  go-up   go-down


2. Precetti FA, Prieto Mde C, Pietrantonio A, González B: [Mixed carcinoid-adenocarcinoma in transverse colon]. Acta Gastroenterol Latinoam; 2010 Dec;40(4):357-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed carcinoid-adenocarcinoma in transverse colon].
  • [Transliterated title] Tumor mixto carcinoide-adenocarcinoma de colon transverso.
  • The following case is a 69-year-old woman with a presumptive diagnosis of adenocarcinoma in transverse colon, which was diagnosed by pathology as a mixed carcinoid-adenocarcinoma tumor after surgery.
  • We discuss in the following report the diagnosis, the therapeutic conduct and its results.
  • We point out with particular consideration that, due to the lack of information related to the functional behaviour and clinical characteristics of these mixed tumors, more studies, analysis, follow-up and descriptions are necessary to perform future diagnosis and therapeutic procedures.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoid Tumor / diagnosis. Colon, Transverse / pathology. Colonic Neoplasms / diagnosis. Mixed Tumor, Malignant / diagnosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21381410.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Crane SJ, Locke GR 3rd, Harmsen WS, Diehl NN, Zinsmeister AR, Melton LJ 3rd, Romero Y, Talley NJ: Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol; 2007 Aug;102(8):1596-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsite-specific risk factors for esophageal and gastric adenocarcinoma.
  • BACKGROUND: The incidence rates of adenocarcinoma involving specific gastric and esophageal subsites are changing significantly, but the risk factors associated with those subsite changes remain controversial.
  • We aimed to describe the site-specific risk factors associated with adenocarcinoma of the stomach and esophagus.
  • METHODS: Using the Rochester Epidemiology Project, all cases of gastric and esophageal adenocarcinoma among Olmsted County, Minnesota, residents first diagnosed between 1971 and 2000 were identified.
  • RESULTS: A total of 186 incident cases of gastric or esophageal adenocarcinoma were identified between 1971 and 2000, in Olmsted County.
  • Gastroesophageal reflux disease (GERD) was a significant risk factor for both esophageal (OR 5.5, 95% CI 1.2-25) and esophagogastric junction adenocarcinoma (OR 13.0, 95% CI 1.7-99), but not for either proximal or distal gastric cancer.
  • CONCLUSIONS: This identification of distinct risk factors by subsite supports the concept that esophageal and gastric adenocarcinomas are two different diseases.
  • Adenocarcinoma of the junction is probably a form of esophageal cancer and should not be coded with gastric neoplasms.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2008 Feb;103(2):492-3 [18289219.001]
  • (PMID = 17459024.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


Advertisement
4. Barbour AP, Jones M, Brown I, Gotley DC, Martin I, Thomas J, Clouston A, Smithers BM: Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol; 2010 Sep;17(9):2494-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors.
  • BACKGROUND: Knowledge of factors related to outcome is vital for the selection of therapeutic alternatives for patients with early (T1) esophageal adenocarcinoma.
  • This study was undertaken to determine predictors of lymphatic spread and prognostic factors for T1 esophageal adenocarcinoma following esophagectomy.
  • MATERIALS AND METHODS: A prospectively maintained database identified 85 patients with T1 esophageal adenocarcinoma who underwent esophagectomy without neoadjuvant therapy.
  • CONCLUSIONS: Risk stratification is possible for patents with T1 esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Lymph Nodes / pathology. Lymphatic Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophagectomy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349213.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Wang C, Zhou XG: [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Apr;35(4):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma].
  • OBJECTIVE: To study the expression of CDX2 in normal and tumor tissues, and to evaluate the value of CDX2 immunostaining in the diagnosis of gastrointestinal adenocarcinoma.
  • RESULTS: CDX2 was strongly expressed in surface epithelium of 13 samples of normal intestine and in ductal epithelium of 8 samples of normal pancreas, as well as in 47 samples (92.2%) of colonic adenocarcinoma and 58 samples (66.9%) of gastric adenocarcinoma.
  • The positivity rates were as follows: ovarian mucinous adenocarcinoma 15.6% (10/64), pancreatic cancer 33.3% (3/9), thyroid cancer 27.3% (3/11) and extrahepatic biliary cancer 25% (4/16).
  • CONCLUSIONS: CDX2 is expressed mainly in normal epithelium of intestinal tract and small pancreatic ducts, as well as in primary adenocarcinoma of gastrointestinal tract.
  • CDX2 may thus play an important role in distinguishing primary non-intestinal adenocarcinoma from metastatic adenocarcinoma of gastric or colorectal primary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastrointestinal Neoplasms / diagnosis. Homeodomain Proteins / metabolism
  • [MeSH-minor] Colonic Neoplasms / diagnosis. Colonic Neoplasms / metabolism. Female. Gastrointestinal Tract / chemistry. Gastrointestinal Tract / pathology. Humans. Immunohistochemistry. Male. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776981.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


6. Singh RP, Raina K, Sharma G, Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res; 2008 Dec 1;14(23):7773-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
  • Herein, for the first time, we investigated the effect and associated mechanisms of silibinin phosphatidylcholine (silybin-phytosome) on established prostate tumors in transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
  • RESULTS: Dietary silibinin inhibited the growth of prostate tumors (up to 60%, P < 0.001) and suppressed tumor progression from prostatic intraepithelial neoplasia to differentiated adenocarcinoma and poorly differentiated adenocarcinoma, with a complete absence of poorly differentiated adenocarcinoma at higher doses.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):403-10 [17574861.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):104-8 [18181052.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2043-50 [18339887.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):156-81 [18166163.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2567-74 [17916909.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5617-20 [11059749.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] BioDrugs. 2001;15(7):465-89 [11520257.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3063-9 [12036915.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Prostate. 2002 Sep 1;52(4):253-63 [12210485.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):525-32 [12479270.001]
  • [Cites] Urol Res. 2003 Feb;30(6):347-55 [12599013.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:156-64 [9027613.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1920-9 [9581834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5 [10377442.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1188-202 [15558015.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1053-69 [16205633.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):359-71 [16633338.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):63-9 [16728325.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):139-46 [17077998.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):413-9 [17826663.001]
  • [CommentIn] Clin Cancer Res. 2008 Dec 1;14(23):7581-2 [19047081.001]
  • (PMID = 19047104.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102514-05; United States / NCI NIH HHS / CA / R01 CA102514; United States / NCI NIH HHS / CA / R01 CA102514-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Silymarin; 0 / Vimentin; 0 / silybin-phytosome; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS82719; NLM/ PMC2639624
  •  go-up   go-down


7. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


8. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • Recent evidence has showed that nephrogenic adenoma is a true "nephrogenic" lesion derived from the proliferation of exfoliated and implanted renal tubular cells in the urinary tract, a process that closely resembles the formation of endometriosis.
  • This new concept has led to the identification of renal transcription factor PAX2 as a diagnostic marker for nephrogenic adenoma.
  • In this study, we investigated the expression of PAX8 in nephrogenic adenoma and its mimics.
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX2 was also detected in 2 of the 7 clear cell adenocarcinomas of the lower urinary tract.
  • We suggest that PAX8 is an additional marker for identifying nephrogenic adenoma.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


9. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.
  • Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma.
  • Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant).
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


10. Sun JS, Park KJ, Sheen SS, Yoon JK, Yoon SN, Lee KB, Hwang SC: Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer; 2009 Nov;66(2):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
  • PURPOSE: To evaluate the clinical usefulness of fluorodeoxyglucose (FDG)-PET maximal SUV in combination with CT features for differentiation of adenocarcinoma with bronchioloalveolar carcinoma (BAC) from other subtypes of non-small cell lung cancer (NSCLC).
  • We categorized NSCLC into adenocarcinoma with BAC feature and other subtypes.
  • Finally, there were 16 cases of adenocarcinoma with BAC and 109 cases of other NSCLC subtypes included in the study.
  • The diagnostic performances of CT alone, PET alone, and combination of two modalities to predict adenocarcinoma with BAC from other subtypes of NSCLC were calculated.
  • RESULTS: A nodule with a mixed pattern with partly solid and ground glass opacity was significantly more frequent CT feature of an adenocarcinoma with BAC (8/16, 50%) as compared with the other subtypes (2/109, 1.8%) (p<0.0001).
  • Maximal SUV of adenocarcinoma with BAC (mean=7.2) was significantly lower than that of other subtypes of NSCLC (mean=13.33) (p<0.0001).
  • Sensitivity, specificity, PPV, and NPV of CT for differentiating adenocarcinoma with BAC from other subtypes was 50% (8/16), 98.2% (107/109), 80% (8/10), and 93% (107/115), respectively.
  • CONCLUSION: Careful combined assessment of the FDG-PET maximal SUV and CT findings have the potential to differentiate an adenocarcinoma with BAC from other NSCLC subtypes, such as a pure BAC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203812.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Sayles M, Courtney E, Younis F, O'Donovan M, Ibrahim A, Fearnhead NS: Appendiceal mucinous adenocarcinoma presenting as an enterocutaneous fistula in an incisional hernia. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal mucinous adenocarcinoma presenting as an enterocutaneous fistula in an incisional hernia.
  • Histological evaluation confirmed a well-to-moderately differentiated mucinous adenocarcinoma arising on a background of dysplastic villous adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Bone Transplantation. Hernia, Abdominal / diagnosis. Ilium / surgery. Intestinal Fistula / diagnosis. Postoperative Complications / diagnosis. Tissue and Organ Harvesting
  • [MeSH-minor] Abdominal Abscess / diagnosis. Aged. Appendectomy. Colectomy. Female. Humans. Laparoscopy. Lymph Node Excision. Neoplasm Staging. Reoperation

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Dec;32(6):1525-41 [4757938.001]
  • [Cites] Actas Urol Esp. 2004 Apr;28(4):327-31 [15248407.001]
  • [Cites] J Dermatol. 1987 Apr;14(2):167-9 [3038981.001]
  • [Cites] Dis Colon Rectum. 1988 Feb;31(2):145-50 [3276467.001]
  • [Cites] Surg Gynecol Obstet. 1988 May;166(5):451-3 [2452489.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):129-37 [3285476.001]
  • [Cites] J R Soc Med. 1988 Nov;81(11):668-9 [3210202.001]
  • [Cites] Surgery. 1992 Mar;111(3):244-50 [1542852.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):396-401 [1319813.001]
  • [Cites] Ann Surg. 1994 Jan;219(1):51-7 [8297177.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):848-52 [7634979.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):422-8 [9517651.001]
  • [Cites] Abdom Imaging. 1999 Mar-Apr;24(2):193-5 [10024411.001]
  • [Cites] Am J Proctol. 1963 Dec;14:265-81 [14098730.001]
  • [Cites] Surg Today. 2007;37(9):806-10 [17713739.001]
  • [Cites] Postgrad Med. 2008 Nov;120(4):95-100 [19020371.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):248-55 [18852679.001]
  • [Cites] Cancer J. 2009 May-Jun;15(3):225-35 [19556909.001]
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Arch Esp Urol. 2001 Jun;54(5):451-4 [11494721.001]
  • [Cites] J Int Med Res. 2002 Jul-Aug;30(4):452-6 [12235932.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):432-7 [12749241.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):923-9 [3885692.001]
  • (PMID = 22789695.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3038038
  •  go-up   go-down


12. Antunes AA, Leite KR, Dall'Oglio MF, Crippa A, Nesrallah LJ, Srougi M: Prostate biopsy: is age important for determining the pathological features in prostate cancer? Int Braz J Urol; 2005 Jul-Aug;31(4):331-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We selected 1422 patients with clinical suspicion of PCa; among them, 547 (38.5%) had received a diagnosis of adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137401.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


13. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res; 2006 Jul-Aug;26(4B):2909-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
  • MATERIALS AND METHODS: Twenty-one primary gastric adenocarcinomas were investigated by comparative genomic hybridization (CGH) and the relationships between genomic abnormalities and histopathological features were evaluated.
  • Chromosomal gains were the most frequent finding, losses occurring only in the diffuse type.
  • 1, where C-MYC is located, was the main finding, exclusively in the intestinal type with metastasis.
  • Gastric adenocarcinomas of differing histopathological features were associated with distinct genetic alterations, supporting the hypothesis that they evolve through distinct genetic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Gene Amplification. Gene Dosage. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886612.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


14. Guzmán-Aránguez A, Olmo N, Turnay J, Lecona E, Pérez-Ramos P, López de Silanes I, Lizarbe MA: Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5. J Cell Biochem; 2005 Jan 1;94(1):178-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5.
  • Thus, we have analyzed changes in annexin A1 (AnxA1), annexin A2 (AnxA2), and annexin A5 (AnxA5) levels and localization in human colon adenocarcinoma cells differentiated by butyrate treatment or by culture in glucose-free inosine-containing medium.
  • Human colon adenocarcinoma cell differentiation is associated with an up-regulation of AnxA1, AnxA2, and AnxA5 and with a subcellular relocation of these proteins.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A1 / metabolism. Annexin A2 / metabolism. Annexin A5 / metabolism. Colonic Neoplasms / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15526283.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Annexin A2; 0 / Annexin A5; 0 / Butyrates; 0 / Proteasome Inhibitors
  •  go-up   go-down


15. Liang WJ, Yan X, Zhang WD, Luo RC: [Garlic oil inhibits cyclin E expression in gastric adenocarcinoma cells]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug;27(8):1241-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Garlic oil inhibits cyclin E expression in gastric adenocarcinoma cells].
  • OBJECTIVE: To explore the inhibitory effect of garlic oil on cyclin E expression in gastric adenocarcinoma cells.
  • METHODS: Human gastric adenocarcinoma SGC7901 cells were cultured routinely and the expressions of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) are detected by immunofluorescent staining and flow cytometry.
  • CONCLUSIONS: The gastric adenocarcinoma SGC7901 cells express TGFalpha and EGFR and possess TGFalpha autocrine and paracrine loops to promote cell proliferation.
  • [MeSH-major] Adenocarcinoma / pathology. Allyl Compounds / pharmacology. Antineoplastic Agents / pharmacology. Cyclin E / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Stomach Neoplasms / pathology. Sulfides / pharmacology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ALLYL SULFIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715037.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Allyl Compounds; 0 / Antineoplastic Agents; 0 / Cyclin E; 0 / Sulfides; 0 / Transforming Growth Factor alpha; 60G7CF7CWZ / allyl sulfide; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


16. Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH: [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Sep;35(9):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
  • OBJECTIVE: To study the gain of chromosome 8 and c-myc gene and lipoprotein lipase gene status in prostatic adenocarcinoma of Chinese patients, and to analyze the relationship between chromosome 8 alterations and Gleason score of prostatic cancer.
  • METHODS: Formalin-fixed, paraffin-embedded prostatic biopsy tissues from 34 Chinese patients with untreated prostatic adenocarcinoma were studied by three-color fluorescence in situ hybridization (FISH) using ProVysion(TM) probe kit.
  • CONCLUSIONS: Alterations in chromosome 8 are common in prostatic adenocarcinoma occurring in Chinese patients.
  • Our data suggest that chromosome 8 alterations may play some roles in the development and progression of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134545.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


17. Xiong SQ, Zhou DH, Lin LZ: [Apoptosis inducing effect of Hechanpian on human lung adenocarcinoma A549 cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Jun;30(6):607-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Apoptosis inducing effect of Hechanpian on human lung adenocarcinoma A549 cells].
  • OBJECTIVE: To study the apoptosis inducing effects of Hechanpian (HCP) on human lung adenocarcinoma A549 cells.


18. Rüschoff J, Aust D, Hartmann A: [Colorectal serrated adenoma: diagnostic criteria and clinical implications]. Verh Dtsch Ges Pathol; 2007;91:119-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal serrated adenoma: diagnostic criteria and clinical implications].
  • More than 40 years ago Morson (1962) coined the paradigm that adenomas are the main precursors of colorectal carcinoma (CRC) whereas hyperplastic polyps are "non-neoplastic" lesions without cancer risk.
  • Later-on (1988) this was supported by Vogelstein's molecular adenoma-carcinoma progression model with APC mutations being a key-initiating molecular event (classic adenoma-carcinoma pathway).
  • These polyps form the hallmark of a third "serrated (neoplasia) pathway" exhibiting a hyperplastic polyp-like morphology characterized by serrated crypt epithelium.
  • In contrast to adenomatous polyps with readily apparent cytological atypia (dysplasia) the feature of dysplasia in serrated polyps is architectural distortion.
  • Today four categories of serrated lesions can be delineated: (i) the most frequent classic hyperplastic polyp (HP, 80-90%), followed by (ii) sessile serrated adenoma (SSA, 15-20%) and (iii) by the rare traditional serrated adenoma (TSA, < 1%).
  • Whereas HPP are benign, SSA are probably slowly progressing lesions and TSA as well as SSA with APC-type adenomatous atypias (iv. mixed SSA) indicate increased cancer risk.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Colonic Polyps / pathology. Diagnosis, Differential. Genes, APC. Humans. Hyperplasia / pathology. Mutation


19. Geisler JP, Linnemeier GC, Manahan KJ: Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium. Int J Gynaecol Obstet; 2007 Jul;98(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: The purpose is to determine the rate of lymph node metastases in women with endometrioid adenocarcinoma of the endometrium (EAE) undergoing systematic lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymph Node Excision. Lymphatic Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490668.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD: Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol; 2008 Jun;32(6):810-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
  • The histologic heterogeneity of lung adenocarcinoma creates a variety of complex challenges to pathologists in analyzing the various subtypes.
  • Current classification schemas do not take into account the major subtype.
  • We analyzed 100 cases for clinical, pathologic, and molecular features using a modification of the 2004 World Health Organization (WHO) classification to record the major component in the mixed subtype tumors.
  • The most common major histologic subtype was papillary (37%) followed by acinar (30%), solid (25%) and bronchioloalveolar (7%) carcinoma (BAC), although no pure BACs were seen.
  • Papillary adenocarcinoma strongly correlated with EGFR mutation (P<0.001) and gene profile Cluster 1 (P=0.006) with weaker correlations with low grade (P=0.038) and favorable behavior in Stage 1 patients (P=0.047).
  • Micropapillary subtype correlated strongly with EGFR mutation (P<0.001) and weakly with Cluster 1 (P=0.030).
  • Solid adenocarcinoma strongly correlated with gene profile Cluster 3 (P=0.001) and worse survival (P=0.001).
  • Cluster 3 strongly correlated with heavier smoking (P<0.001), larger tumor size (P<0.001), solid subtype (P<0.001), and poor grade (P=0.004); weak correlations were found with KRAS mutation (P=0.025).
  • Higher stage (P<0.001), grade (P<0.001), and solid subtype (P=0.001) correlated with shorter survival.
  • Our data suggest that EGFR mutations are associated with papillary adenocarcinoma and gene profile Cluster 1.
  • We discovered this only because we used a comprehensive approach examining in detail all histologic subtypes and we modified the 2004 WHO mixed subtype to include the major histologic subtype.
  • As we do not know the major genetic pathways of 30% to 70% of lung adenocarcinomas, the comprehensive histologic subtyping we propose gives advantage for recognition of unanticipated histologic-genetic correlations that might not be detected using classification systems that focus primarily on specific aspects of adenocarcinomas such as BAC or EGFR mutations.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391747.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084999; United States / NCI NIH HHS / CA / UO1CA84999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Shaco-Levy R, Piura B: Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma. J Obstet Gynaecol Res; 2008 Apr;34(2):279-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma.
  • Only five cases of pure ovarian adenocarcinoma recurring as carcinosarcoma have been documented in the literature.
  • There are no documented cases of endometrial adenocarcinoma recurring as metaplastic carcinoma.
  • We report of a case of endometrial adenocarcinoma, endometrioid type, recurring as metaplastic carcinoma showing sarcomatous differentiation.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinosarcoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412798.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X: MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res; 2009 Sep 15;15(18):5744-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
  • PURPOSE: Esophageal adenocarcinoma is a highly aggressive malignancy that frequently develops from Barrett's esophagus, a premalignant pathologic change occurring in the lower end of the esophagus.
  • Identifying Barrett's esophagus patients at high risk of malignant transformation is essential to the prevention of esophageal adenocarcinoma.
  • Although microRNA (miRNA) expression signatures have been associated with the etiology and prognosis of several types of cancers, their roles in the development of esophageal adenocarcinoma have not been extensively evaluated.
  • EXPERIMENTAL DESIGN: In this study, we analyzed the expression patterns of 470 human miRNAs using Agilent miRNA microarray in 32 disease/normal-paired tissues from 16 patients diagnosed with Barrett's esophagus of either low- or high-grade dysplasia, or esophageal adenocarcinoma.
  • Similar findings were observed for esophageal adenocarcinoma, but not for Barrett's esophagus with low-grade dysplasia.
  • The expression patterns of selected miRNAs were further validated using quantitative reverse transcription real-time PCR in an independent set of 75 pairs of disease/normal tissues.
  • Finally, we identified several miRNAs that were involved in the progressions from low grade-dysplasia Barrett's esophagus to esophageal adenocarcinoma.
  • CONCLUSIONS: We showed that miRNAs were involved in the development and progression of esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Dec 15;98(12):2740-1 [14669301.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Mol Carcinog. 1995 Dec;14(4):286-93 [8519418.001]
  • [Cites] Am J Gastroenterol. 1998 Jun;93(6):911-5 [9647017.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):283-9 [16421561.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):228-33 [16380711.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] RNA. 2007 Jan;13(1):151-9 [17105992.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Cell. 2007 Apr 6;129(1):147-61 [17382377.001]
  • [Cites] Nat Genet. 2007 May;39(5):582-3 [17460676.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Nat Med. 2007 May;13(5):613-8 [17468766.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4553-5 [17510380.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):26-33 [18172293.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2690-5 [18451233.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Brain Res. 2008 Oct 21;1236:185-93 [18710654.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):562-72; discussion 572-3 [10801023.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jun;12(6):649-54 [10912484.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Jul;15(7):730-6 [10937677.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • (PMID = 19737949.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA111922-02; United States / NCI NIH HHS / CA / R01 CA111922; United States / NCI NIH HHS / CA / CA111922; United States / NCI NIH HHS / CA / R01 CA111922-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS125002; NLM/ PMC2745487
  •  go-up   go-down


23. Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang PC: Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol; 2010 Mar;27(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
  • OBJECTIVE: Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are involved in the tumorigenesis and regulation of cell metabolism via Akt signaling.
  • Thus, in this study, we hypothesize that there exist correlations between EGFR mutation status and [(18)F]FDG uptake of advanced lung adenocarcinoma.
  • METHODS: From May 2004 to April 2008, patients with stage IIIB or IV lung adenocarcinoma who underwent [(18)F]FDG PET and EGFR mutation analysis before receiving any treatment were eligible to participate in this study.
  • RESULTS: Seventy-seven lung adenocarcinoma patients were included in this study.
  • The [(18)F]FDG uptake was significantly higher in EGFR-mutant (mean SUV(MAX) = 10.5 +/- 4.7) than wild-type (8.0 +/- 3.3) lung adenocarcinoma patients (P = 0.008).
  • CONCLUSIONS: Among Asian patients with advanced lung adenocarcinoma, those with higher SUV(MAX) on the [(18)F]FDG PET are more likely to carry EGFR mutations.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Mutation. Positron-Emission Tomography. Radiopharmaceuticals. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Fluorodeoxyglucose F18. Genetic Testing. Humans. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6):664-73 [18520811.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3255-60 [15310769.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1238-43 [10622535.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):963-9 [16152581.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2566-74 [15852359.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3837-44 [11051227.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3340-6 [16785471.001]
  • [Cites] Lung Cancer. 2003 Jan;39(1):55-61 [12499095.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):998-1004 [17047648.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):369-79 [15967114.001]
  • [Cites] FEBS Lett. 2001 Mar 16;492(3):199-203 [11257494.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Eur J Nucl Med. 2000 Dec;27(12):1778-85 [24578007.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1136-43 [15718309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Radiother Oncol. 2000 Jun;55(3):317-24 [10869746.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5659-67 [17020967.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2745-53 [18509184.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31372-8 [8940145.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1285-92 [12663716.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14 ):2651-7 [12860940.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):659-66 [11902536.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jul;130(1):151-9 [15999056.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41 [15292385.001]
  • [Cites] Lung Cancer. 2002 Feb;35(2):179-87 [11804691.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1419-27 [17532932.001]
  • (PMID = 19130320.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


24. Tu H, Han H, Zhou FJ, Li YH, Qin ZK, Liu ZW: [Extramammary Paget's disease of the scrotum with underlying sweat gland adenocarcinoma: a report of six cases with literature review]. Ai Zheng; 2009 Aug;28(8):879-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extramammary Paget's disease of the scrotum with underlying sweat gland adenocarcinoma: a report of six cases with literature review].
  • BACKGROUND AND OBJECTIVE: Extramammary Paget's disease (EMPD) of the scrotum with sweat gland adenocarcinoma is a rare malignant tumor.
  • This study was to summarize the clinicopathologic characteristics of scrotum Paget's disease with underlying sweat gland adenocarcinoma, and analyze the treatment outcome.
  • METHODS: Clinical data of six scrotum Paget's disease patients with sweat gland adenocarcinoma, treated in Sun Yat-sen University Cancer Center from 1964 to 2004, were analyzed with literature review.
  • RESULTS: The typical manifestation of scrotum Paget's disease with sweat gland adenocarcinoma was eczematoid-like skin changes.
  • CONCLUSION: The primary lesion resection plus uni-inguinal lymphadenectomy is the major treatment for scrotum Paget's disease with underlying sweat gland adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Genital Neoplasms, Male / surgery. Neoplasms, Multiple Primary / surgery. Paget Disease, Extramammary / surgery. Sweat Gland Neoplasms / surgery
  • [MeSH-minor] Aged. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Scrotum / pathology. Scrotum / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664337.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


25. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT: Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res; 2006 Aug 1;12(15):4598-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
  • However, the role of ANXA1 in esophageal adenocarcinoma is unclear.
  • Our goal was to evaluate ANXA1 expression and determine its prognostic significance in adenocarcinoma of the esophagus and esophagogastric junction.
  • EXPERIMENTAL DESIGN: This study included 104 consecutive patients with primary resected esophageal and esophagogastric junction adenocarcinomas (11 stage I, 24 stage II, 53 stage III, and 16 stage IV).
  • CONCLUSION: Our results indicate that high ANXA1 expression is frequent in esophageal and esophagogastric junction adenocarcinomas, correlates with more advanced pathologic T stage and the presence of distant metastasis, and is an independent prognostic factor for patient survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A1 / biosynthesis. Esophageal Neoplasms / metabolism. Esophagogastric Junction / metabolism. Esophagogastric Junction / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Analysis. Tissue Array Analysis. Treatment Outcome


26. Iiizumi M, Hosokawa M, Takehara A, Chung S, Nakamura T, Katagiri T, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H: EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci; 2006 Nov;97(11):1211-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.
  • To isolate novel diagnostic markers and drug targets for pancreatic ductal adenocarcinoma (PDAC), we previously performed expression profile analysis of PDAC cells using a genome-wide cDNA microarray combined with laser microdissection.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Northern. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965393.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.10.1 / Receptor, EphA4
  •  go-up   go-down


27. Wu YQ, Song Z, Zhou CH, Xing SH, Pei DS, Zheng JN: Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo. Oncol Rep; 2010 Nov;24(5):1179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo.
  • In this study, we investigated the mRNA and protein expressions of UII and its receptor (UT-R) in human lung adenocarcinoma A549 cells, and the effect of exogenous UII on the proliferation of A549 cells in vitro and in vivo.
  • Reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis showed that both mRNAs and proteins of UII and UT-R were obviously expressed in human lung adenocarcinoma A549 cells.
  • Nude mice bearing human lung adenocarcinoma A549 cells treated with UII showed a significant increase in tumor volume and tumor weight compared with control group.
  • These findings suggest that UII may contribute to the pathogenesis of human lung adenocarcinoma as an autocrine/paracrine growth stimulating factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Lung Neoplasms / metabolism. Receptors, G-Protein-Coupled / biosynthesis. Urotensins / biosynthesis. Urotensins / pharmacology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878108.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / UTS2R protein, human; 0 / Urotensins; 9047-55-6 / urotensin II
  •  go-up   go-down


28. Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP: Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features. AJR Am J Roentgenol; 2009 Sep;193(3):W238-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features.
  • OBJECTIVE: The purpose of this study was to investigate the MRI and MR spectroscopy features of mucinous adenocarcinoma of the prostate.
  • CONCLUSION: MRI and MR spectroscopy do not appear to provide the ability to reliably detect the lakes of extracellular mucin seen in mucinous adenocarcinoma of the prostate.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2000 Jan;43(1):17-22 [10642727.001]
  • [Cites] J Endourol. 2008 Apr;22(4):789-94 [18366322.001]
  • [Cites] AJR Am J Roentgenol. 2008 Mar;190(3):656-65 [18287436.001]
  • [Cites] Urology. 2006 Oct;68(4):825-30 [17070361.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Eur Radiol. 2000;10(6):885-91 [10879695.001]
  • [Cites] Magn Reson Med. 2001 Dec;46(6):1079-87 [11746572.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S69-75; discussion S75-6 [14610414.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):299-308 [2409826.001]
  • [Cites] J Magn Reson Imaging. 1992 Sep-Oct;2(5):597-600 [1327313.001]
  • [Cites] J Magn Reson Imaging. 1997 Jul-Aug;7(4):745-57 [9243397.001]
  • [Cites] Urology. 1999 Jul;54(1):141-4 [10414741.001]
  • [Cites] Radiology. 2004 Dec;233(3):701-8 [15564406.001]
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):126-37 [16007671.001]
  • (PMID = 19696265.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059897; United States / NIBIB NIH HHS / EB / 1 T32 EB001631-01A1; United States / NIBIB NIH HHS / EB / T32 EB001631; United States / NCI NIH HHS / CA / CA059897-16; United States / NCI NIH HHS / CA / R01 CA059897-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS165996; NLM/ PMC2801739
  •  go-up   go-down


29. Buskens CJ, Ten Kate FJ, Obertop H, Izbicki JR, van Lanschot JJ: Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia. Dis Esophagus; 2008;21(6):488-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia.
  • The aim of the present study was to identify the incidence of potentially relevant micrometastatic disease in patients with histologically node-negative esophageal adenocarcinoma and to analyze the sensitivity and specificity of three different immunohistochemical assays.
  • From a consecutive series of 79 patients who underwent a transthoracic resection with extended 2-field lymphadenectomy, all 20 patients with pN0 esophageal adenocarcinoma were included in this study.
  • In 114 of the 559 negative lymph nodes (20.4%), positive single cells were found that did not demonstrate malignant characteristics.
  • For the detection of clinically relevant micrometastatic disease in patients operated upon for adenocarcinoma of the distal esophagus or gastric cardia, Ber-EP4 is the antibody of first choice because of its high sensitivity and specificity.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840133.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


30. Nakanishi K, Kumaki F, Hiroi S, Mukai M, Ikeda E, Kawai T: Mre11 expression in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med; 2006 Sep;130(9):1330-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mre11 expression in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
  • OBJECTIVE: To investigate Mre11 in atypical adenomatous hyperplasia (AAH) and nonmucinous bronchioloalveolar carcinoma (NMBAC), an issue not previously explored.
  • CONCLUSIONS: On this basis, we suggest that the part played by Mre11 in telomere maintenance may not be important for the progression of the adenoma-carcinoma (AAH-NMBAC) sequence in the lung, although some role for it in carcinogenesis cannot be completely ruled out.
  • [MeSH-major] Adenocarcinoma / pathology. DNA-Binding Proteins / genetics. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948520.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MRE11A protein, human; 0 / RNA, Messenger
  •  go-up   go-down


31. M A M, Pera G, Agudo A, Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Manjer J, Johansson I, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Slimani N, Jenab M, Ferrari P, Riboli E, González CA: Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study. Int J Cancer; 2007 Oct 01;121(7):1618-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study.
  • A previous case-control study reported reduced risk of gastric cardia adenocarcinomas associated with cereal fiber, but not with fruit or vegetable fiber.
  • This study prospectively examines associations between fiber from different food sources and incident gastric adenocarcinomas (GC) among more than 435,000 subjects from 10 countries participating in the European Prospective Investigation into Cancer and Nutrition study.
  • [MeSH-major] Adenocarcinoma / prevention & control. Dietary Fiber / administration & dosage. Edible Grain. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582605.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105630924
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T, Ried T: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol; 2005 Mar 20;23(9):1826-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.
  • PURPOSE: There is a wide spectrum of tumor responsiveness of rectal adenocarcinomas to preoperative chemoradiotherapy ranging from complete response to complete resistance.
  • CONCLUSION: Our results suggest that pretherapeutic gene expression profiling may assist in response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.
  • [MeSH-major] Adenocarcinoma / genetics. RNA, Neoplasm / genetics. Rectal Neoplasms / genetics
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Radiotherapy, Adjuvant

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774776.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS663101; NLM/ PMC4721601
  •  go-up   go-down


33. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK, Saqi A: CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg; 2009 Mar;137(3):615-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.
  • This study aimed to determine whether expression of these molecules is associated with clinicopathologic features and disease-free survival in non-small cell lung carcinoma.
  • Staining intensity was compared with tumor histotype, TNM stage, and disease-free survival; correlation was assessed by using the Fisher's exact test, and Kaplan-Meier and Cox multivariate proportional hazards regression analysis.
  • The prognostic relevance of CXCR4 was dependent on its subcellular location: in univariate analysis intense nuclear staining was significantly associated with lower T classification and improved disease-free survival in patients with adenocarcinoma, whereas cytomembranous staining was associated with distant metastasis and decreased disease-free survival.
  • On multivariate analysis, cytomembranous CXCR4 expression conferred a significantly worse disease-free survival (relative risk, 2.8; 95% confidence interval, 1.4-5.7; P = .004).
  • CONCLUSIONS: Cytomembranous expression of the chemokine receptor CXCR4 in adenocarcinoma of the lung is an independent risk factor associated with worse disease-free survival, whereas nuclear staining confers a survival benefit.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Chemokine CXCL12 / biosynthesis. Lung Neoplasms / metabolism. Lung Neoplasms / mortality. Receptors, CXCR4 / biosynthesis
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258077.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4
  •  go-up   go-down


34. Maekawa S, Iwasaki A, Shirakusa T, Enatsu S, Kawakami T, Kuroki M, Kuroki M: Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res; 2007 Nov-Dec;27(6A):3735-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
  • Whether or not the expression of VEGF-C, -D, and VEGFR-3 correlates with clinicopathological factors in patients with T1 lung adenocarcinoma was analysed.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Lymphatic Metastasis / genetics. Vascular Endothelial Growth Factor C / genetics. Vascular Endothelial Growth Factor D / genetics. Vascular Endothelial Growth Factor Receptor-3 / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970036.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


35. Ilha MR, Loretti AP, Barros CS, Gimeno EJ, Martin CA: Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow. Vet Pathol; 2005 Jan;42(1):74-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow.
  • The diagnosis of papillary adenocarcinoma of the extrahepatic bile duct was based on the morphologic features of the neoplasm and evidence of local invasion.
  • [MeSH-major] Adenocarcinoma, Papillary / veterinary. Bile Duct Neoplasms / veterinary. Bile Ducts, Extrahepatic / pathology. Cattle Diseases / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657275.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


36. Maillard P, Loock B, Grierson DS, Laville I, Blais J, Doz F, Desjardins L, Carrez D, Guerquin-Kern JL, Croisy A: In vitro phototoxicity of glycoconjugated porphyrins and chlorins in colorectal adenocarcinoma (HT29) and retinoblastoma (Y79) cell lines. Photodiagnosis Photodyn Ther; 2007 Dec;4(4):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro phototoxicity of glycoconjugated porphyrins and chlorins in colorectal adenocarcinoma (HT29) and retinoblastoma (Y79) cell lines.
  • BACKGROUND: Retinoblastoma is the most common malignant intraocular tumor in children.
  • METHOD: In this paper, we report about the screening of the in vitro photocytotoxicity of hydrophenylporphyrins and chlorins and their glycoconjugated derivatives in a human retinoblastoma cell line (Y79) and for comparison in a colorectal adenocarcinoma cell line (HT29).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25047563.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH: EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med; 2009 Mar;24(1):48-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and KRAS mutations in patients with adenocarcinoma of the lung.
  • METHODS: This study was conducted to investigate the prevalence of EGFR and KRAS mutations and their correlation with clinical variables in Korean patients with adenocarcinoma of the lung.
  • Formalin-fixed adenocarcinoma specimens from 104 randomly selected patients diagnosed at Kosin University Gospel Hospital from October 1996 to January 2005 were used for the study.
  • The presence of an EGFR mutation was not associated with gender, smoking history, histological grade, age, bronchioalveolar components, or cancer stage in patients with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. DNA, Neoplasm / genetics. Lung Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jan;119(1):21-6 [10612756.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5727-30 [11479207.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S [12235219.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):3-9 [12422308.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2658-63 [12860941.001]
  • [Cites] Cancer Sci. 2003 Jun;94(6):540-7 [14529588.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Chest. 2004 Aug;126(2):347-51 [15302716.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5738-41 [3048648.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1037-43 [2197591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Cancer Res. 1992 May 1;52(9 Suppl):2665s-2669s [1562997.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 19;1378(1):F21-59 [9739759.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Chest. 2005 Mar;127(3):768-77 [15764756.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] Virchows Arch. 2005 May;446(5):483-8 [15815931.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2799-803 [11306446.001]
  • (PMID = 19270482.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2687655
  •  go-up   go-down


38. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y, Oka M: Synchronus presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe. Intern Med; 2006;45(5):287-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronus presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe.
  • A histological diagnosis (small cell carcinoma) was obtained by bronchoscopic examination including a transbronchial lung biopsy (TBLB).
  • While the nodule in the left S(1+2) (small cell carcinoma) had become completely necrotic by the time the final diagnosis was made after resection of the left upper lobe, histological diagnosis of the nodule in the left S3 revealed a well differentiated adenocarcinoma.
  • Synchronous presentation of early-stage lung cancer consisting of small cell carcinoma and adenocarcinoma was identified in the same left upper division of the lung.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595996.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


39. Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, Went P, Oertli D: Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol; 2010 Jul;36(7):670-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus.
  • INTRODUCTION: Tumor-infiltrating lymphocytes (TILs) and forkhead box transcription factor positive (FoxP3(+)) regulatory T-lymphocytes (TREGs) have been analyzed in a variety of tumors but not in oesophageal adenocarcinoma.
  • PATIENTS AND METHODS: Tissue from 130 adenocarcinomas of the oesophagus was re-evaluated in the centre and periphery of tumour, respectively, using immunohistochemical staining with anti-CD3, anti-CD4, anti-CD8, anti-CD25 and anti-FoxP3 antibodies.
  • We found no morphologic evidence that TREGs suppress immunological response, represented by the infiltration of CD8(+) cells.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Esophageal Neoplasms / mortality. Esophageal Neoplasms / pathology. Forkhead Transcription Factors / metabolism. Lymphocytes, Tumor-Infiltrating. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Research Design. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510571.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


40. Jin G, Xu L, Shu Y, Tian T, Liang J, Xu Y, Wang F, Chen J, Dai J, Hu Z, Shen H: Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis; 2009 Jun;30(6):987-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population.
  • This significant association was more prominent among female (P for heterogeneity: 0.044), non-smokers (P for heterogeneity: 0.054) and/or the subjects with adenocarcinoma (P for heterogeneity: 0.058).
  • These results suggest that genetic variants in 5p15.33, especially in TERT gene, may also predispose the susceptibility of lung cancer, especially adenocarcinoma, in Chinese population.
  • [MeSH-major] Asian Continental Ancestry Group. Carcinoma, Non-Small-Cell Lung / genetics. Chromosomes, Human, Pair 5 / genetics. Genetic Predisposition to Disease. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Case-Control Studies. Female. Humans. Male. Membrane Proteins / genetics. Middle Aged. Neoplasm Proteins / genetics. Telomerase / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369581.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLPTM1L protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


41. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F, Shimada H: Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res; 2006 Jan-Feb;26(1B):639-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types.
  • PATIENTS AND METHODS: A total of 1,558 patients with primary gastric adenocarcinomas were enrolled in this study.
  • CONCLUSION: Therapeutic strategies should be based on the histological type of the tumor in patients with poorly-differentiated gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation / physiology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739333.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


42. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, De Gaetani C, Filetti S, Bianchi G, Russo D: Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology; 2010 Apr;75(4):773-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the sodium/iodide symporter in human prostate adenocarcinoma.
  • OBJECTIVE: To analyze expression of the sodium/iodide symporter (NIS) in tissue specimen from a large series of patients with prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Symporters / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19969326.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Symporters; 0 / sodium-iodide symporter; 9679TC07X4 / Iodine
  •  go-up   go-down


43. Beer AJ, Wieder HA, Lordick F, Ott K, Fischer M, Becker K, Stollfuss J, Rummeny EJ: Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology; 2006 May;239(2):472-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.
  • PURPOSE: To prospectively evaluate multi-detector row computed tomography (CT) in the assessment of early response during neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction (AEG).
  • Survival without disease progression was estimated in all patients according to the Kaplan-Meier method.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiography. Esophageal Neoplasms / radiography. Esophageal Neoplasms / radiotherapy. Esophagogastric Junction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 16543584.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Risio M: The natural history of adenomas. Best Pract Res Clin Gastroenterol; 2010 Jun;24(3):271-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of adenomas.
  • It is well known that adenomas represent the morphologically categorised precursor of the vast majority of colorectal cancers.
  • Only few adenomas actually develop invasive cancer (progressive adenomas), although every adenoma has the capacity of malignant evolution.
  • Most adenomas stabilise their progression or even regress.
  • Easily identifiable but widely ranged pathological features (size, architectural growth, type, grade and gross organisation of dysplasia) are predictive of their natural history in terms of potential of cancerisation and duration of the adenoma-carcinoma sequence.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology. Colorectal Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Disease Progression. Humans. Neoplasm Invasiveness. Phenotype

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [ReprintIn] Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):397-406 [20833344.001]
  • (PMID = 20510828.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 59
  •  go-up   go-down


45. Ke B, Liang H, Zhang RP, Wang XJ, Wang G, Zhao JZ: [Prognostic analysis on primary duodenal adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May;13(5):357-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis on primary duodenal adenocarcinoma].
  • OBJECTIVE: To investigate the prognostic factors of primary duodenal adenocarcinoma.
  • METHODS: The medical records of 67 patients with primary duodenal adenocarcinoma treated in our hospital from January 1990 to December 2005 were retrospectively analyzed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Duodenal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499305.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


46. Koga Y, Yao T, Hirahashi M, Kumashiro Y, Ohji Y, Yamada T, Tanaka M, Tsuneyoshi M: Flat adenoma-carcinoma sequence with high-malignancy potential as demonstrated by CD10 and beta-catenin expression: a different pathway from the polypoid adenoma-carcinoma sequence. Histopathology; 2008 Apr;52(5):569-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat adenoma-carcinoma sequence with high-malignancy potential as demonstrated by CD10 and beta-catenin expression: a different pathway from the polypoid adenoma-carcinoma sequence.
  • The aim was to examine phenotypic expression in colorectal neoplasia and to elucidate changes in such expression through the adenoma-carcinoma sequence.
  • METHODS AND RESULTS: We examined the expression of various proteins immunohistochemically in 111 flat [non-polypoid growth (NPG)] colorectal neoplasms, categorized into 28 low-grade (NPG-LGN), 44 high-grades (NPG-HGN) and 39 cases of invasive neoplasia (NPG-IN), as well as in 96 polypoid [polypoid growth (PG)] neoplasms, categorized into 26 PG-LGN, 39 PG-HGN and 31 PG-IN according to the Vienna classification.
  • CD10 was more frequently expressed in NPG than in PG neoplasia.
  • No difference in p53 expression was found between NPG and PG neoplasia.
  • It is important to ensure that NPG neoplasia is not overlooked if cases of CD10+ carcinoma are to be detected at an early stage.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Neprilysin / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Disease Progression. Early Diagnosis. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18370954.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / beta Catenin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


47. Sadok A, Bourgarel-Rey V, Gattacceca F, Penel C, Lehmann M, Kovacic H: Nox1-dependent superoxide production controls colon adenocarcinoma cell migration. Biochim Biophys Acta; 2008 Jan;1783(1):23-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nox1-dependent superoxide production controls colon adenocarcinoma cell migration.
  • Using Nox1 siRNA, we show that Nox1-dependent superoxide production affects the migration of HT29-D4 colonic adenocarcinoma cells on collagen-I.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Movement. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. NADPH Oxidase / metabolism. Superoxides / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023288.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Integrin alpha2beta1; 11062-77-4 / Superoxides; EC 1.13.11.31 / Arachidonate 12-Lipoxygenase; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


48. Liang S, Yang ZL: [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb;32(1):109-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats].
  • (1) The incidence of pancreatic cancer in Group A within 3 - 5 months was 48.7% (18/37), including 17 cases of pancreatic ductal adenocarcinoma and 1 case of fibrosarcoma.
  • The incidence of pancreatic cancer in Group B was 33.3% (12/36), including 11 pancreatic ductal adenocarcinoma and 1 fibrosarcoma.
  • The positive rates of KiSS-1mRNA in Group A or Group B with ductal adenocarcinoma were significantly lower than those in Group A or Group B without ductal adenocarcinoma (P<0.01).
  • TSA may have an inhibitive effect on the carcinogenesis and the growth of pancreatic ductal adenocarcinoma in rats, and KiSS-1 may play an important role in inhibiting the invasion and metastasis of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344598.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Kiss1 protein, rat; 0 / Kisspeptins; 0 / Proteins; 0 / RNA, Messenger; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


49. Nishigami T, Kataoka TR, Torii I, Sato A, Tamura K, Hirano H, Hida N, Ikeuchi H, Tsujimura T: Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis. Pathol Res Pract; 2010 Dec 15;206(12):846-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis.
  • Ulcerative colitis (UC) complicated by colonic lymphoma is rare, although UC is often accompanied by adenocarcinoma of the colon.
  • A concurrent existence of adenocarcinoma and lymphoma in a patient with UC is extremely rare, and has not yet been analyzed at the molecular level.
  • We report a 64-year-old female patient with concomitant adenocarcinoma and diffuse large B-cell lymphoma (DLBCL) in the colon of UC.
  • The colon adenocarcinomas had a mutation in MSH6 gene, DNA methylation in CDKN2A gene, and increased microsatellite instability (MSI), although these genetic changes were not recognized in either DLBCL or non-neoplastic UC mucosa.
  • The adenocarcinomas and the non-neoplastic UC mucosa were EBV-negative.
  • Our case presented here clearly shows that the development of adenocarcinoma and lymphoma in the colon with UC was caused by individual mechanisms.
  • [MeSH-major] Adenocarcinoma / genetics. Colitis, Ulcerative / pathology. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Genes, p16. Herpesvirus 4, Human. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology
  • [MeSH-minor] B-Lymphocytes / pathology. DNA Methylation. DNA Mutational Analysis. DNA, Neoplasm. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / diagnosis. Female. Humans. Immunohistochemistry. Microsatellite Instability. Middle Aged. Mutation. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20846793.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


50. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • In the cases of primary ovarian or peritoneal carcinoma, the mucosal tumor within the cervix, which was discovered at the same time as the ovarian or peritoneal neoplasm, raised the possibility of synchronous independent lesions or metastasis from the cervix to the ovary or peritoneum.
  • Positive staining for WT1, p53, and estrogen receptor in the cases of serous carcinoma and an absence of human papillomavirus by linear array genotyping in all cases was of value in excluding a primary cervical neoplasm, although these ancillary studies are supplementary to microscopic examination.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


51. Alfaro L, Bermas H, Fenoglio M, Parker R, Janik JS: Are patients who have had a tracheoesophageal fistula repair during infancy at risk for esophageal adenocarcinoma during adulthood? J Pediatr Surg; 2005 Apr;40(4):719-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are patients who have had a tracheoesophageal fistula repair during infancy at risk for esophageal adenocarcinoma during adulthood?
  • The authors present a case of a 46-year-old woman who had esophageal adenocarcinoma after having had a tracheoesophageal fistula (TEF) repair as an infant.
  • A Medline search, which identified 2 other patients in the world literature who developed esophageal cancer (squamous cell carcinoma [J Pediatr Surg 36(4) (2001) 629-630] and adenocarcinoma [J Pediatr Surg 24(8) (1989) 741-744]) after TEF repair, was performed.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Postoperative Complications. Tracheoesophageal Fistula / surgery


52. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer; 2009;9:119
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: BM developed in 27, and 32% of patients at 1 and 2 years of diagnosis with adenocarcinoma (RR 5.2; 95% CI, 1.002-29; p = 0.05) and CEA > or = 40 ng/mL (RR 11.4; 95% CI, 1.7-74; p < 0.01) as independent associated factors.
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Immunoassay / methods. Immunohistochemistry. Luminescent Measurements / methods. Lung / metabolism. Lung / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Prospective Studies. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Survival Analysis


53. Porta M, López T, Pumarega J, Jariod M, Crous-Bou M, Marco E, Rifà J, Grimalt JO, Malats N, Real FX, PANKRAS II Study Group: In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations. Mutagenesis; 2009 Nov;24(6):513-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations.
  • While KRAS activation is a fundamental initiating event in the aetiopathogenesis of pancreatic ductal adenocarcinoma (PDA), environmental factors influencing the occurrence and persistence of KRAS mutations remain largely unknown.
  • Given that KRAS mutations are the most frequent abnormality of oncogenes in human cancers, and the lifelong accumulation of OCs in humans, refutation or replication of the findings is required before any implications are assessed.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Pancreatic Ductal / genetics. Genes, ras. Hydrocarbons, Chlorinated / blood. Mutation. Pancreatic Neoplasms / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797353.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coffee; 0 / Hydrocarbons, Chlorinated; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


54. Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, Gillies SD, Sondel PM: Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res; 2009 Aug 01;15(15):4875-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
  • EXPERIMENTAL DESIGN: In this preclinical study, we sought to enhance the antitumor effect of RFA by combining it with huKS-IL2 immunocytokine [tumor-specific monoclonal antibody fused to interleukin-2 (IL2)] in mice bearing CT26-KS colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Antibodies, Monoclonal / therapeutic use. Colonic Neoplasms / therapy. Immunologic Memory / drug effects. Interleukin-2 / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2004 Apr;35(4):424-9 [15116322.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):299-306 [15578688.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):593-600 [11005558.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1500-7 [11245457.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Cancer Immunol Immunother. 2008 Dec;57(12):1891-902 [18438664.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1586-94 [9362156.001]
  • [Cites] Gene Ther. 1999 Aug;6(8):1469-74 [10467371.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):155-69 [15069676.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4024-9 [15173017.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):338-47 [12734080.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S231-44 [12354841.001]
  • [Cites] Radiology. 2000 Dec;217(3):633-46 [11110923.001]
  • [Cites] J Exp Med. 1990 Oct 1;172(4):1101-14 [1698909.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):381-7 [11461868.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1633-41 [8833913.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):450-8 [15024305.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Aug;15(4):703-21 [11676280.001]
  • [Cites] J Immunother. 2004 May-Jun;27(3):232-9 [15076141.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):183-91 [17874276.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6496-500 [14559842.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):256-63 [17458595.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):960-73 [16843866.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):896-905 [16953240.001]
  • [Cites] J Immunother. 2004 May-Jun;27(3):211-9 [15076138.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Br J Radiol. 2004 Sep;77(921):713-23 [15447955.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jan;53(1):41-52 [14504825.001]
  • [Cites] Cancer Res. 1989 Jul 1;49(13):3680-8 [2471587.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] Radiology. 1997 Nov;205(2):367-73 [9356616.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):1951-9 [9816154.001]
  • [Cites] Am J Surg. 1999 Dec;178(6):592-9 [10670879.001]
  • [Cites] Gut. 2002 Jan;50(1):1-5 [11772955.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Nat Rev Immunol. 2003 May;3(5):413-25 [12766763.001]
  • [Cites] Oncologist. 2006 Jul-Aug;11(7):801-8 [16880239.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1139-46 [16424051.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4948-55 [9354462.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:254-61; discussion 261-2 [10911918.001]
  • [Cites] Breast Dis. 2001;12:131-40 [15687613.001]
  • (PMID = 19638464.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / F31 GM067386; United States / NIGMS NIH HHS / GM / GM067386; United States / NCI NIH HHS / CA / R01 CA032685; United States / NCI NIH HHS / CA / T32-CA090217; United States / NCI NIH HHS / CA / R01 CA087025-04; United States / NCI NIH HHS / CA / P30 CA014520; United States / NIGMS NIH HHS / GM / T32 GM008692; United States / NCI NIH HHS / CA / CA87025; United States / NCI NIH HHS / CA / CA032685; United States / NCI NIH HHS / CA / CA14520; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / R01 CA032685-25; United States / NCI NIH HHS / CA / R01 CA087025
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Interleukin-2; 339986-90-2 / tucotuzumab celmoleukin
  • [Other-IDs] NLM/ NIHMS123966; NLM/ PMC2735865
  •  go-up   go-down


55. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R, Jankowski J: A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res; 2007 Oct 1;13(19):5869-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
  • PURPOSE: At presentation, most cases of adenocarcinoma of the esophagus (ACE) are inoperable.
  • Although chemotherapy can prolong survival, patients eventually die as a result of refractory disease.
  • Three patients had a partial response and seven had stable disease, giving a disease control rate (partial response + stable disease) of 37%.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Esophageal Neoplasms / drug therapy. Gene Expression Regulation, Neoplastic. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908981.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ki-67 Antigen; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


56. Epstein JI: Prostatic ductal adenocarcinoma: a mini review. Med Princ Pract; 2010;19(1):82-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic ductal adenocarcinoma: a mini review.
  • Prostatic ductal adenocarcinomas may arise either in large primary periurethral prostatic ducts or in the peripheral prostatic ducts.
  • Ductal adenocarcinomas are composed of tall columnar cells arranged in cribriform, papillary, solid, single glands, and PIN-like patterns.
  • Other than the prostatic intraepithelial neoplasia (PIN)-like ductal pattern, which behaves like Gleason pattern 3, ductal adenocarcinoma is comparable to Gleason pattern 4 prostate cancer.
  • Ductal adenocarcinoma can have a patchy basal cell layer and typically expresses prostate-specific antigen (PSA) immunohistochemically.
  • Mimickers of ductal adenocarcinoma include prostatic urethral polyps, hyperplastic benign prostate glands, high-grade PIN, colorectal adenocarcinoma, and papillary urothelial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996627.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


57. Mai KT, Burns BF, Stinson WA, Morash C: The 3-dimensional structure of isolated and small foci of prostatic adenocarcinoma: the morphologic relationship between prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 3-dimensional structure of isolated and small foci of prostatic adenocarcinoma: the morphologic relationship between prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
  • BACKGROUND: Transitional histopathologic changes from high-grade prostatic intraepithelial neoplasia (HGPIN) into early prostatic adenocarcinoma (PAC) have not been well studied to date.
  • At the junctions between benign epithelia with or without HGPIN and malignant epithelia, there were transitional lesions with HGPIN involving small ducts and acini.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536307.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Hachem S, Khauli RB, Salti I: Surgical adrenal diseases. J Med Liban; 2005 Apr-Jun;53(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are four adrenal disorders in which surgery is the treatment of choice: pheochromocytoma, Cushing's syndrome due to ACTH-independent adrenal disease (adenoma, carcinoma or autonomous hyperplasia), primary aldosteronism due to an adrenal adenoma and some adrenal non-functional "incidentilomas".
  • Definitive diagnosis by accurate biochemical assessment of the functional status of the adrenal lesion.

  • Genetic Alliance. consumer health - Adrenal Diseases.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604998.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Lebanon
  • [Number-of-references] 26
  •  go-up   go-down


59. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist; 2010;15(12):1310-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
  • BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).
  • The primary endpoint was to determine the disease control rate (DCR) as measured by the Response Evaluation Criteria in Solid Tumors (complete response, partial response [PR], and stable disease) at 6 weeks.
  • PATIENTS AND METHODS: Patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and with progressive pancreas adenocarcinoma following treatment with gemcitabine were eligible.
  • The DCR was 21.6%; one patient (1.4%) had a PR and 15 patients (20.3%) had stable disease as their best response.
  • CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Pancreatic Neoplasms / drug therapy. Pyrroles / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):193-8 [19047305.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1439-47 [9849429.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1873-82 [19276273.001]
  • [Cites] Oncology. 2009;76(4):254-61 [19246950.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Curr Drug Metab. 2009 Jun;10(5):470-81 [19689244.001]
  • [Cites] J Gastrointest Cancer. 2009;40(1-2):1-9 [19513861.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85 [19828009.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7 [20130876.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:69-73 [10436789.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39 [15648955.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):369-75 [16012797.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]
  • [Cites] BMC Cancer. 2008;8:82 [18373843.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2046-52 [18756532.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166 [11992800.001]
  • (PMID = 21148613.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00397787
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227926
  •  go-up   go-down


60. Van Kerkhóve F, Coenegrachts K, Steyaert L, Van Den Berghe I, Casselman JW: Collision tumor in the ileum: a rare combination of an adenocarcinoma and small cell neuroendocrine tumor. JBR-BTR; 2006 Sep-Oct;89(5):258-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor in the ileum: a rare combination of an adenocarcinoma and small cell neuroendocrine tumor.
  • Pathology revealed a rare ileal collision tumor consisting of an adenocarcinoma and a small cell neuroendocrine tumor with peritoneal metastasis of neuroendocrine origin and coincidental benign lesions on both ovaries.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Villous / diagnosis. Adenomatous Polyps / diagnosis. Carcinoma, Small Cell / diagnosis. Ileal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Tomography, X-Ray Computed. Ultrasonography
  • [MeSH-minor] Adenofibroma / diagnosis. Adenofibroma / pathology. Adenofibroma / surgery. Aged. Cystadenoma / diagnosis. Cystadenoma / pathology. Cystadenoma / surgery. Female. Fibroma / diagnosis. Fibroma / pathology. Fibroma / surgery. Humans. Ileum / pathology. Ileum / surgery. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Liver / pathology. Liver / surgery. Lymphatic Metastasis / pathology. Mesentery / pathology. Mesentery / surgery. Omentum / pathology. Omentum / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Ovary / pathology. Peritoneum / pathology. Peritoneum / surgery


61. Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H: IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol; 2010 Apr;41(4):477-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 expression is correlated with histologic grade of lung adenocarcinoma.
  • This study aimed to determine the correlation of insulin-like growth factor II mRNA binding protein 3 expression with histologic grade of lung adenocarcinoma.
  • Eighty-nine cases, including 11 atypical adenomatous hyperplasias, 10 pure bronchioloalveolar carcinomas, 36 well-differentiated adenocarcinomas and 41 moderately or poorly differentiated adenocarcinomas, were immunohistochemically studied using a monoclonal antibody against insulin-like growth factor II mRNA binding protein 3.
  • Twenty-nine (70.7%) of 41 moderately to poorly differentiated adenocarcinomas were positive for insulin-like growth factor II mRNA binding protein 3, with 26 (89.7%) tumors demonstrating either a strong staining or staining in greater than 30% of tumor cells.
  • Four (40.0%) of 10 bronchioloalveolar carcinomas and 13 (36.1%) of 36 well-differentiated adenocarcinomas exhibited insulin-like growth factor II mRNA binding protein 3 positivity with a variable degree and percentage of tumor cells staining.
  • When bronchioloalveolar carcinomas were present in a pure form or as a component of adenocarcinomas, positive insulin-like growth factor II mRNA binding protein 3 staining was always patchy, with less than 20% of tumor cells stained.
  • Overall, the frequency of positive insulin-like growth factor II mRNA binding protein 3 staining was lower in bronchioloalveolar carcinomas and well-differentiated adenocarcinomas compared to moderately/poorly differentiated adenocarcinomas (P < .01).
  • No insulin-like growth factor II mRNA binding protein 3 signal was detected in any case of atypical adenomatous hyperplasia.
  • These findings show that insulin-like growth factor II mRNA binding protein 3 is strongly and diffusely expressed in a large proportion of moderately/poorly differentiated lung adenocarcinomas, in particular in the solid component of mixed subtype adenocarcinomas, less frequently expressed in well-differentiated adenocarcinomas and bronchioloalveolar carcinomas, and negative in atypical adenomatous hyperplasias.
  • The higher frequency of expression in moderately/poorly differentiated adenocarcinomas suggests that insulin-like growth factor II mRNA binding protein 3 expression may be associated with an aggressive biological behavior.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Humans. Hyperplasia. Immunohistochemistry. Lung / metabolism. Lung / pathology. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc.
  • (PMID = 20004948.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


62. Sartori G, Cavazza A, Bertolini F, Longo L, Marchioni A, Costantini M, Barbieri F, Migaldi M, Rossi G: A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. Am J Clin Pathol; 2008 Feb;129(2):202-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
  • Atypical adenomatous hyperplasia (AAH) is considered the preinvasive lesion of pulmonary adenocarcinoma, and mutations of EGFR, HER2, and K-ras are involved in the early stage of lung adenocarcinoma carcinogenesis, also predicting clinical response to anti-EGFR small molecule inhibitors.
  • We analyzed 18 cases of primary lung adenocarcinoma with concomitant AAH foci from 13 patients for mutations of EGFR (exons 18-21), HER2 (exons 19-20), and K-ras (exon 2) by direct sequencing polymerase chain reaction.
  • Among mutated cases, concordant mutations of EGFR or K-ras in adenocarcinoma and related AAH were observed in 5 (63%) of 8 cases.
  • In particular, 3 of 4 adenocarcinomas with EGFR mutations (all L858R point mutations in women, never or former smokers) had a concomitant and identical mutation in AAH, and 2 of 4 adenocarcinomas with K-ras mutations (both at codon 12 in women, a never and a current smoker) showed the same mutation in concomitant AAH.
  • Mutations of EGFR and K-ras genes represent an early event in lung adenocarcinomagenesis, and AAH convincingly seems to be a precursor lesion in a subset of cases of adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Genes, ras. Hyperplasia / genetics. Lung Neoplasms / genetics. Precancerous Conditions / genetics. Receptor, Epidermal Growth Factor / genetics


63. Paczos TA, Ackers S, Odunsi K, Lele S, Mhawech-Fauceglia P: Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy. Int J Gynecol Pathol; 2010 Mar;29(2):193-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy.
  • Subsequent vaginal smears revealed high-grade vaginal intraepithelial neoplasia (VAIN III) on Pap smear with positive human papilloma virus (HPV) testing.
  • A biopsy performed at the time of the second laser procedure revealed endocervical-type well-differentiated adenocarcinoma, associated with VAIN III.
  • The vaginectomy specimen showed residual adenocarcinoma associated with VAIN-III and extensive vaginal adenosis with free resection margins.
  • This is the second reported case in the literature of adenocarcinoma arising in vaginal adenosis after 5-fluorouracil.
  • Herein, we highlight these important findings and shed some light on the pathogenesis of vaginal adenosis and the subsequent development of vaginal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173507.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA108456
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; U3P01618RT / Fluorouracil
  •  go-up   go-down


64. Reinblatt M, Pin RH, Bowers WJ, Federoff HJ, Fong Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann Surg Oncol; 2005 Dec;12(12):1025-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.
  • A novel HSV amplicon expressing 10 x HRE/sFlk-1 was genetically engineered (HSV10 x HRE/sFlk-1).Human pancreatic adenocarcinoma cells (AsPC1) were transduced with HSV10 x HRE/sFlk-1 and incubated in normoxia (21% oxygen) or hypoxia (1% oxygen).
  • Tumor hypoxia can thus be used to direct antiangiogenic therapy to pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / administration & dosage. Hypoxia-Inducible Factor 1. Neovascularization, Physiologic / drug effects. Pancreatic Neoplasms / therapy. Vascular Endothelial Growth Factor Receptor-2 / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244806.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 76416; United States / NCI NIH HHS / CA / R01 CA/DK 80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Hypoxia-Inducible Factor 1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


65. Kirkpatrick JP, Hardee ME, Snyder SA, Peltz CM, Zhao Y, Brizel DM, Dewhirst MW, Blackwell KL: The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res; 2006 Feb;165(2):192-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma.
  • This study randomized rats to treatment with low-dose or high-dose darbepoetin alfa or a placebo to determine the effect of darbepoetin alfa on the pO2, growth and response to radiation therapy of R3230 mammary adenocarcinoma.
  • In this nonanemic animal model of mammary adenocarcinoma, darbepoetin alfa does not significantly alter tumor growth or radioresponsiveness, even though it improves oxygenation when administered at high doses.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Erythropoietin / analogs & derivatives. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / therapy. Oxygen / metabolism. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518899.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA40355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 11096-26-7 / Erythropoietin; 15UQ94PT4P / Darbepoetin alfa; S88TT14065 / Oxygen
  •  go-up   go-down


66. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H: Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer; 2010 Jan 5;102(1):144-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.
  • BACKGROUND: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the development of adenocarcinoma.
  • To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer.
  • METHODS: Tissue microarrays were constructed from tumour samples from 54 patients with all stages of the disease.
  • CONCLUSIONS: These results suggest that alterations in DNA MMR pathways are common in SBAs, similar to what is observed in large bowel adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Duodenal Neoplasms / genetics. Gene Expression Profiling. Immunophenotyping. Neoplasm Proteins / biosynthesis. Oncogenes

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Arch Pathol Lab Med. 2007;131(1):18-43 [19548375.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):115-29 [10903528.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Food Chem Toxicol. 2001 Mar;39(3):209-28 [11278053.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1331-46 [11571750.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):158-64 [11791187.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):439-47 [12163369.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1551-7 [12627520.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):913-9 [13679455.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):181-90 [14732226.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):712-8 [15166663.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1352-9 [15371952.001]
  • [Cites] Nat Genet. 1995 Jan;9(1):48-55 [7704024.001]
  • [Cites] Jpn J Cancer Res. 1995 Apr;86(4):357-60 [7775257.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):100-5 [8606540.001]
  • [Cites] Dig Dis. 1996 Jul-Aug;14(4):245-57 [8843980.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):127-35 [9207270.001]
  • [Cites] Cell. 1998 Oct 2;95(1):29-39 [9778245.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):573-80 [16501564.001]
  • [Cites] Br J Surg. 2006 Nov;93(11):1424-32 [17022010.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):48-56 [17631130.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):808-16 [17951204.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [CommentIn] Br J Cancer. 2010 Oct 12;103(8):1305; author reply 1306 [20842127.001]
  • (PMID = 19935793.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2813754
  •  go-up   go-down


67. Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d'Arcy JA, Collins DJ, Padhani AR: Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology; 2010 Dec;257(3):643-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
  • PURPOSE: To investigate the histopathologic and dynamic magnetic resonance (MR) imaging correlates of intrinsic susceptibility-weighted (ISW) MR imaging in patients with primary human breast adenocarcinoma and to assess the relationship between baseline transverse relaxation rate (R2*) and T2* relaxivity change (ΔR2*) and the response to neoadjuvant chemotherapy (NAC).
  • Baseline adenocarcinoma R2* (n = 31) and ΔR2* (n = 27) were correlated with final pathologic response.
  • CONCLUSION: R2* is influenced by blood volume in untreated breast adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Contrast Media. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Image Interpretation, Computer-Assisted. In Situ Hybridization, Fluorescence. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Neoplasm, Residual / pathology. Prospective Studies. ROC Curve. Statistics, Nonparametric. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010
  • (PMID = 20858850.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


68. Gutierrez LS: The role of thrombospondin 1 on intestinal inflammation and carcinogenesis. Biomark Insights; 2008;3:171-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) quite common in the United States and other Western countries.
  • Patients suffering IBD are at greater risk of developing colorectal adenocarcinoma than the general population.
  • Both, the adenoma-carcinoma and the inflammation-carcinogenesis processes are characterized by active angiogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19079771.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK067901-01A1; United States / NIDDK NIH HHS / DK / R15 DK067901; United States / NIDDK NIH HHS / DK / R15 DK067901-01A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; ApcMin + mouse / CD36 / angiogenesis / inflammatory bowel disease / transforming growth factor beta 1
  •  go-up   go-down


69. Wallace AE, Sales KJ, Catalano RD, Anderson RA, Williams AR, Wilson MR, Schwarze J, Wang H, Rossi AG, Jabbour HN: Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Res; 2009 Jul 15;69(14):5726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma.
  • The prostaglandin F(2alpha) (PGF(2alpha)) receptor (FP) is elevated in endometrial adenocarcinoma.
  • This study found that PGF(2alpha) signaling via FP regulates expression of chemokine (C-X-C motif) ligand 1 (CXCL1) in endometrial adenocarcinoma cells.
  • Similarly, CXCL1 was elevated in response to 100 nmol/L PGF(2alpha) in endometrial adenocarcinoma explant tissue.
  • The expression of CXCR2 colocalized to neutrophils in endometrial adenocarcinoma and increased neutrophils were present in endometrial adenocarcinoma compared with normal endometrium.
  • In conclusion, our results show a novel PGF(2alpha)-FP pathway that may regulate the inflammatory microenvironment in endometrial adenocarcinoma via neutrophil chemotaxis.
  • [MeSH-major] Adenocarcinoma / pathology. Chemokine CXCL1 / metabolism. Endometrial Neoplasms / pathology. Neutrophils / metabolism. Receptors, Prostaglandin / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / drug effects. Chemotaxis, Leukocyte / drug effects. Dinoprost / pharmacology. Endometrium / metabolism. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Mice. Mice, Nude. Microscopy, Fluorescence. Neoplasm Transplantation. Neoplasms, Experimental / genetics. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Receptors, Interleukin-8B / genetics. Receptors, Interleukin-8B / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Transplantation, Heterologous

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):411-5 [19147552.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1853-60 [14996749.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):5034-40 [15067085.001]
  • [Cites] J Exp Med. 1990 May 1;171(5):1797-802 [2185333.001]
  • [Cites] Prostaglandins. 1993 May;45(5):413-26 [8321911.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2632-6 [8300593.001]
  • [Cites] Hum Reprod. 1994 Aug;9(8):1406-9 [7989497.001]
  • [Cites] J Histochem Cytochem. 1995 Jan;43(1):97-102 [7822770.001]
  • [Cites] Mol Endocrinol. 1998 Jun;12(6):815-24 [9626657.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] J Biol Chem. 1999 Feb 12;274(7):4309-18 [9933632.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4356-62 [10485483.001]
  • [Cites] Inflamm Res. 2004 Oct;53(10):576-84 [15597153.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3071-7 [16540656.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):768-78 [16510280.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jun 27;252(1-2):191-200 [16701939.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9 [17062666.001]
  • [Cites] Infect Immun. 2006 Dec;74(12):6829-38 [16982839.001]
  • [Cites] Dig Dis Sci. 2006 Dec;51(12):2188-97 [17078003.001]
  • [Cites] Annu Rev Med. 2007;58:239-52 [17100552.001]
  • [Cites] Cell Tissue Res. 2007 Apr;328(1):197-206 [17186309.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):1949-57 [17621625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 [18077379.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9 [18061438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2640-5 [18268320.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2466-77 [17968320.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2579-87 [18451219.001]
  • [Cites] Gut. 2008 Jun;57(6):780-7 [18272544.001]
  • [Cites] Scand J Immunol. 2008 Sep;68(3):328-36 [18565119.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7750-9 [18829529.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9754-62 [19047154.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):53-62 [10647998.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4647-59 [11030154.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9366-74 [11112786.001]
  • [Cites] Hum Reprod. 2001 Jun;16(6):1065-75 [11387270.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):1018-25 [11861527.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1825-32 [12679480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9 [12835412.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • (PMID = 19549892.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601481; United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01/2(61014); United Kingdom / Medical Research Council / / U.1276.00.004.00002.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL1; 0 / Receptors, Interleukin-8B; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; B7IN85G1HY / Dinoprost
  • [Other-IDs] NLM/ PMC2712458; NLM/ UKMS27211
  •  go-up   go-down


70. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, Belinsky SA: Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis; 2009 Jul;30(7):1132-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers.
  • Twenty-six genes, 14 identified through methylation in colon and breast cancers, were evaluated using primary lung adenocarcinomas (n = 175) from current, former and never smokers.
  • Prevalence for methylation of TNFRSF10C, BHLHB5 and BOLL was significantly higher in adenocarcinomas from never smokers than smokers.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Apr 4;21(15):2328-33 [11948416.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):9005-14 [18974146.001]
  • [Cites] Hum Mol Genet. 2003 Jan 15;12(2):169-75 [12499397.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):47-51 [12538348.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4620-5 [12907641.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):53-9 [12925956.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4842-8 [12941804.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):786-92 [14999791.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1926-33 [15070965.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6569-80 [15247904.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):59-66 [15386433.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):400-5 [15578700.001]
  • [Cites] Lung Cancer. 2005 Mar;47(3):309-14 [15713514.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):503-10 [15700311.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):407-14 [15818620.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1001-10 [16331886.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1371-5 [16452191.001]
  • [Cites] BMC Biochem. 2006;7:2 [16417632.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):46-51 [16533425.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3338-44 [16540689.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):691-9 [16705123.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10621-9 [17079487.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):85-93 [17114206.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):157-62 [11905807.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):469-71 [17290053.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):472-8 [17290054.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):561-70 [17290066.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6087-92 [17947472.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1707-14 [18339850.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1211-22 [18318435.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):3049-56 [18413776.001]
  • [Cites] PLoS Genet. 2007 Jul;3(7):e110 [17616978.001]
  • [Cites] PLoS Med. 2008 May 27;5(5):e114 [18507500.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1623-30 [18623126.001]
  • [Cites] PLoS Genet. 2008;4(8):e1000155 [18704159.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3669-75 [12473575.001]
  • (PMID = 19435948.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 043318; United States / NIEHS NIH HHS / ES / R01 ES 008801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2704285
  •  go-up   go-down


71. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, Nagasaka T, Nomura S: Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol; 2006 Aug 1;94(2):138-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
  • BACKGROUND AND OBJECTIVES: There were a few reports of a large number of patients with clear cell adenocarcinoma (CCA) of the ovary because of the low incidence of CCA.
  • Thus, substaging is quite important for comparison of prognoses between histologies, and CCA showed poorer prognoses than serous adenocarcinoma in stages IIIb and IIIc.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Ovarian Neoplasms / mortality
  • [MeSH-minor] Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Follow-Up Studies. Humans. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16847906.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J: Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia; 2005 Jan;7(1):17-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.
  • Molecular analyses have demonstrated mutations in the K-ras gene at codon 12 in the majority of pancreatic ductal adenocarcinomas (PDACs).
  • The described duct lesions were reclassified according to the nomenclature for pancreatic intraepithelial neoplasia (PanIN), and the molecular methods for detecting K-ras were reviewed.
  • In CP, K-ras mutations were only found after a disease duration of 3 years.
  • [MeSH-minor] Adenocarcinoma / genetics. Humans

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):464-8 [10440377.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1958-64 [12806629.001]
  • [Cites] Eur J Surg Oncol. 2003 Aug;29(6):491-6 [12875854.001]
  • [Cites] Pancreas. 2003 Oct;27(3):e57-62 [14508142.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):635-41 [14520703.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):508-17 [12942322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14247-52 [14603032.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Curr Gastroenterol Rep. 2004 Apr;6(2):111-8 [15191688.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1243-7 [14963016.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):480-3 [15239123.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:7 [12537585.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):230-6 [1309358.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):138-43 [8439212.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):953-6 [8439969.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Int J Pancreatol. 1993 Dec;14(3):237-44 [8113625.001]
  • [Cites] BMJ. 1994 Sep 10;309(6955):648-51 [8086990.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):227-31 [8536861.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):306-10 [8536876.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):841-8 [10543256.001]
  • [Cites] Virchows Arch. 1999 Nov;435(5):461-8 [10592048.001]
  • [Cites] J Epidemiol Community Health. 1999 Nov;53(11):702-9 [10656099.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Histopathology. 2000 Jun;36(6):481-7 [10849088.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Int J Pancreatol. 2000 Apr;27(2):93-103 [10862508.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2495-504 [10861425.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]
  • [Cites] J Pathol. 2000 Sep;192(1):81-9 [10951404.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • [Cites] Dig Dis. 2001;19(1):15-23 [11385247.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):581-90 [11469690.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):798-802 [11787853.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):441-7 [11950919.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Feb;16(1):1-16 [12063821.001]
  • [Cites] Pancreatology. 2001;1(5):405-15 [12120217.001]
  • [Cites] Pancreatology. 2001;1(6):581-6 [12120240.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):551-4 [12189555.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):139-46 [11266517.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):812-7 [11309327.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):734-43 [11375580.001]
  • [Cites] Int J Pancreatol. 1996 Oct;20(2):85-93 [8968863.001]
  • [Cites] Surgery. 1997 Jan;121(1):42-9 [9001550.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Int J Pancreatol. 1997 Jun;21(3):205-17 [9322119.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]
  • [Cites] Mutat Res. 1998 Sep 20;405(2):125-33 [9748537.001]
  • [Cites] Pancreas. 1998 Nov;17(4):323-4 [9821172.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):326-32 [10023699.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):602-10 [10374765.001]
  • [Cites] Int J Clin Pharmacol Ther. 2002 Aug;40(8):354-67 [12467304.001]
  • (PMID = 15720814.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1490318
  •  go-up   go-down


73. Suzuki N, Higashiguchi A, Hasegawa Y, Matsumoto H, Oie S, Orikawa K, Ezawa S, Susumu N, Miyashita K, Aoki D: Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Hum Cell; 2005 Sep;18(3):147-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells.
  • Among various types of surface epithelial ovarian carcinoma, clear cell adenocarcinoma often has a particularly poor prognosis even when diagnosed in stage I.
  • The present study was conducted using cell lines derived from ovarian clear cell adenocarcinoma in order to identify genes associated with the acquisition of malignant potential by this type of cancer.
  • Two cell lines derived from ovarian clear cell adenocarcinoma (RMG-I and RMG-V), with different levels of invasive potential in an invasion assay, were used.
  • The findings obtained using these cell lines derived from ovarian clear cell adenocarcinoma indicate that integrin alpha3 may associated with the acquisition of malignant potential by clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Gene Expression Regulation, Neoplastic. Integrin alpha3 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 May 20;77(4):477-8 [8187171.001]
  • [Cites] Hum Cell. 1988 Dec;1(4):426-35 [3154025.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1992 Jul;44(7):827-32 [1500804.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1995-2004 [12796361.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Gynecol Oncol. 1991 Dec;43(3):195-7 [1752486.001]
  • [Cites] Jpn J Cancer Res. 1991 Jul;82(7):854-61 [1715339.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):1-11 [8476198.001]
  • (PMID = 17022147.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Integrin alpha3
  •  go-up   go-down


74. Tirkes AT, Duerinckx AJ: Adenocarcinoma of the ileum in Crohn disease. Abdom Imaging; 2005 Nov-Dec;30(6):671-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the ileum in Crohn disease.
  • Small bowel adenocarcinoma develops in 1.5% of patients who have longstanding Crohn disease and is very rarely diagnosed preoperatively because of its rarity, overlapping imaging features, and lack of reported cases.
  • [MeSH-major] Adenocarcinoma / radiography. Crohn Disease / complications. Ileal Diseases / radiography


75. Zhang ZY, Zhao ZR, Jiang L, Li JC, Gao YM, Cui DS, Wang CJ, Schneider J, Wang MW, Sun XF: Nup88 expression in normal mucosa, adenoma, primary adenocarcinoma and lymph node metastasis in the colorectum. Tumour Biol; 2007;28(2):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nup88 expression in normal mucosa, adenoma, primary adenocarcinoma and lymph node metastasis in the colorectum.
  • OBJECTIVES: It was the aim of this study to investigate Nup88 expression in normal colorectal mucosa, adenoma, adenocarcinoma and lymph node metastasis, as well as the relationship between Nup88 expression and clinicopathological features.
  • METHODS: Nup88 expression was examined by immunohistochemistry in 84 normal mucosa samples, 32 adenomas, 181 primary adenocarcinomas, and 18 lymph node metastases from colorectal tumour patients.
  • The frequency of strong Nup88 expression was increased from normal mucosa or adenoma to primary tumour and lymph node metastasis (p < 0.0001).
  • There was no significant difference in the expression between normal mucosa and adenoma (p = 0.41).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Nuclear Pore Complex Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17264541.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NUP88 protein, human; 0 / Nuclear Pore Complex Proteins
  •  go-up   go-down


76. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS: Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol; 2008 Dec;180(6):2409-13; discussion 2414
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database.
  • PURPOSE: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma.
  • MATERIALS AND METHODS: The CaPSURE registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years.
  • Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36 and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes.
  • CONCLUSIONS: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function.
  • Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Quality of Life. Registries
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930270.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Brugha RE, Sherwood W, Scarsbrook A, Mitchell C, Lakhoo K: Rectal adenocarcinoma following cranio-spinal radiotherapy for cerebellar medulloblastoma. Pediatr Surg Int; 2007 Jun;23(6):605-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal adenocarcinoma following cranio-spinal radiotherapy for cerebellar medulloblastoma.
  • The authors present a case of a 16-year-old female diagnosed with rectal adenocarcinoma 10 years after receiving cranio-spinal radiotherapy for a cerebellar medulloblastoma.
  • While the risk of a second malignancy is recognised to be increased in children previously treated with radiotherapy, rectal adenocarcinoma is a rare presentation.
  • [MeSH-major] Adenocarcinoma / etiology. Radiotherapy / adverse effects. Rectal Neoplasms / etiology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 2005 Mar;22(2):89-101 [15804994.001]
  • [Cites] J Korean Med Sci. 2000 Aug;15(4):475-7 [10983702.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2848-53 [9704738.001]
  • [Cites] Eur J Pediatr Surg. 2005 Jun;15(3):210-2 [15999318.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):338-41 [11719875.001]
  • [Cites] Semin Pediatr Surg. 2006 Feb;15(1):37-47 [16458845.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):556-60 [8888817.001]
  • [Cites] Pediatr Surg Int. 2001 Jul;17(5-6):475-7 [11527196.001]
  • (PMID = 17103217.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


79. de La Motte Rouge T, Valent A, Ambrosetti D, Vielh P, Lacroix L: [Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer]. Ann Pathol; 2007 Oct;27(5):353-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Facteurs prédictifs de la réponse aux inhibiteurs de tyrosine kinase ciblant le récepteur à l'EGF dans le cancer bronchique.
  • This rate of response is related to non-smoker status, female gender, adenocarcinoma subtype, and Asian ethnicity.
  • Nevertheless, objective responses or strong long-term stabilizations are observed in patients without any EGFR abnormality.
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Carcinoma, Bronchogenic / drug therapy. Carcinoma, Bronchogenic / genetics. Carcinoma, Bronchogenic / pathology. Female. Gene Amplification. Humans. Male. Mutation


80. Cetiner H, Kir G, Akoz I, Gurbuz A, Karateke A: Large-cell neuroendocrine carcinoma of the cervix associated with cervical-type invasive adenocarcinoma: a report of case and discussion of histogenesis. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):438-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the cervix associated with cervical-type invasive adenocarcinoma: a report of case and discussion of histogenesis.
  • A case of cervical large-cell neuroendocrine carcinoma with mucinous-type cervical adenocarcinoma component adjacent to it is presented, and its histopathogenesis and clinical course are discussed under the light of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Brachytherapy / methods. Carcinoma, Neuroendocrine / pathology. Neoplasm Invasiveness / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445674.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


81. Piura B: Two successful pregnancies after in vitro fertilization and embryo transfer in a patient with endometrial atypical hyperplasia bordering on adenocarcinoma treated conservatively with high-dose progesterone. Gynecol Obstet Invest; 2006;61(1):21-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two successful pregnancies after in vitro fertilization and embryo transfer in a patient with endometrial atypical hyperplasia bordering on adenocarcinoma treated conservatively with high-dose progesterone.
  • Women suffering from anovulatory infertility may develop endometrial hyperplasia and adenocarcinoma due to the unopposed estrogen effect.
  • We present the case of a young infertile woman with endometrial atypical hyperplasia bordering on adenocarcinoma who refused hysterectomy and bilateral salpingo-oophorectomy and achieved two successful pregnancies after conservative treatment with high-dose progesterone followed by in vitro fertilization and embryo transfer.
  • It is concluded that conservative treatment with high-dose progesterone for endometrial hyperplasia and well-differentiated early-stage adenocarcinoma followed by assisted reproductive technologies is an appropriate means for achieving pregnancy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Embryo Transfer. Endometrial Hyperplasia / drug therapy. Fertilization in Vitro. Progesterone / therapeutic use. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16131806.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


82. Harik L, Nassar A: Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Aug;130(8):1223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma.
  • We present a case of a patient who was initially diagnosed with poorly differentiated prostatic adenocarcinoma on prostate needle core biopsy.
  • Positron emission tomographic scan showed increased uptake in para-aortic, paracaval, and retrocaval lymph nodes suspicious for metastatic disease.
  • Left nephrectomy revealed involvement with extranodal Rosai-Dorfman disease.
  • Lymphadenectomy revealed metastatic prostatic adenocarcinoma; however, the lymph nodes did not show evidence of Rosai-Dorfman disease.
  • Isolated involvement of the kidney by Rosai-Dorfman disease is very rare.
  • The combination of prostatic adenocarcinoma and isolated extranodal Rosai-Dorfman disease of the kidney makes this case unique.
  • [MeSH-major] Adenocarcinoma / complications. Histiocytosis, Sinus / complications. Kidney Diseases / complications. Prostatic Neoplasms / complications


83. Sakurai T, Sakashita H, Honjo G, Kasyu I, Manabe T: Gastric foveolar metaplasia with dysplastic changes in Brunner gland hyperplasia: possible precursor lesions for Brunner gland adenocarcinoma. Am J Surg Pathol; 2005 Nov;29(11):1442-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric foveolar metaplasia with dysplastic changes in Brunner gland hyperplasia: possible precursor lesions for Brunner gland adenocarcinoma.
  • Cases of adenocarcinomas developed in Brunner gland hyperplasia (BGH) have been sporadically reported.
  • Herein, we report the morphologic spectrum of hyperplastic changes culminating into dysplasia and carcinoma in 722 cases of BGH listed in our files.
  • Immunohistochemical profiles also supported the concept of a continuous spectrum in carcinogenesis from gastric foveolar hyperplasia through atypical hyperplasia or dysplasia and eventually to frank adenocarcinoma.
  • The results of our study suggest, therefore, that dysplastic and/or carcinomatous change does occur in BGH, that they form the continuous morphologic spectrum, and that papillary foveolar metaplasia may be a precursor lesion in the process of carcinogenesis with a background of BGH.
  • [MeSH-major] Adenocarcinoma / pathology. Brunner Glands / pathology. Precancerous Conditions / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Disease Progression. Female. Humans. Hyperplasia. Male. Metaplasia. Middle Aged. Mucin 5AC. Mucins / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224210.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins
  •  go-up   go-down


84. Kaur H, Buettner H, Salomao DR, Marks RS: Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma. Am J Ophthalmol; 2007 Feb;143(2):369-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
  • PURPOSE: To report transcleral orbital invasion by a radiation- and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
  • METHODS: A 51-year-old female was found to have choroidal metastasis from a previously unknown primary pulmonary adenocarcinoma.
  • RESULTS: A transvitreal aspiration biopsy of the choroidal lesion confirmed the diagnosis of metastatic pulmonary adenocarcinoma.
  • CONCLUSIONS: Despite appropriate external beam radiation therapy (EBRT) and chemotherapy, pulmonary adenocarcinoma metastases to the choroid can continue to grow and may invade the orbit transclerally.
  • [MeSH-major] Adenocarcinoma / secondary. Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Orbital Neoplasms / pathology. Sclera / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance. Eye Enucleation. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiation Tolerance. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258542.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


85. Liu KT, Chan HM, Lin TJ: An unusual presentation of metastatic gastric adenocarcinoma--acute onset of right neck swelling. J Formos Med Assoc; 2007 Jul;106(7):589-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic gastric adenocarcinoma--acute onset of right neck swelling.
  • Fluid accumulation over deep neck space led to the diagnosis of suspected hemorrhage, and central venous thrombosis was found by computed tomography.
  • Subsequently, gastric adenocarcinoma was confirmed after gastroendoscopy.
  • Gastric adenocarcinoma with distal metastases was finally diagnosed.
  • Malignancy, including gastric adenocarcinoma, is one of the causes that should be considered.

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660150.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


86. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med; 2005 Mar;2(3):e73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
  • BACKGROUND: Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1001-10 [15573099.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):303-7 [12042704.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46265-72 [12196540.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5913-9 [15342366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6652-9 [15374980.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2532-9 [15256422.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] J Neurosci Methods. 1993 Nov;50(2):205-16 [8107502.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15435-40 [12594213.001]
  • [Cites] Ann Hematol. 2003 May;82(5):284-9 [12692682.001]
  • [Cites] Hematol J. 2004;5(1):55-60 [14745431.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Chem Biol. 2004 May;11(5):691-701 [15157880.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):294-9 [15236194.001]
  • [CommentIn] PLoS Med. 2005 Mar;2(3):e75 [15736989.001]
  • [CommentIn] PLoS Med. 2005 Sep;2(9):e269 [16173832.001]
  • (PMID = 15737014.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207; United States / NCI NIH HHS / CA / T32 CA 09207
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC549606
  •  go-up   go-down


87. Shimizu K, Itsuzaki Y, Fujii H, Honoki K, Tsujiuchi T: Reduced expression of the Rassf1a gene and its aberrant DNA methylation in pancreatic duct adenocarcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Mol Carcinog; 2008 Feb;47(2):80-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of the Rassf1a gene and its aberrant DNA methylation in pancreatic duct adenocarcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters.
  • Alterations of the Rassf1a gene were investigated in pancreatic duct adenocarcinomas (PDAs) induced by N-nitrosobis(2-oxopropyl)amine (BOP) in hamsters.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinogens / toxicity. DNA Methylation. Nitrosamines / toxicity. Pancreatic Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17849420.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA Primers; 0 / Nitrosamines; 0 / Tumor Suppressor Proteins; 60599-38-4 / nitrosobis(2-oxopropyl)amine
  •  go-up   go-down


88. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Colonic Polyps / genetics. DNA Methylation. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


89. Veshapidze N, Alibegashvili M, Gabunia N, Ramishvili L, Kotrikadze N: Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate. Georgian Med News; 2009 Jan;(166):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate.
  • The aim of our study was to investigate the alterations of the erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate before and six months after castration.
  • Clinical stage of the disease was established at A.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Membrane Permeability / physiology. Erythrocyte Membrane / metabolism. Prostatic Neoplasms / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism
  • [MeSH-minor] Aged. Homeostasis / physiology. Humans. Intracellular Fluid / metabolism. Ion Transport / physiology. Male. Middle Aged. Neoplasm Metastasis. Potassium / metabolism. Sodium / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202209.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 9NEZ333N27 / Sodium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; RWP5GA015D / Potassium
  •  go-up   go-down


90. Feldstein RC, Sood S, Katz S: Small bowel adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2008 Aug;14(8):1154-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma in Crohn's disease.
  • Small bowel neoplastic disease is a rare but dreaded occurrence in Crohn's disease (CD) and the diagnosis is often disguised by nonspecific and varied presenting symptoms mimicking active or obstructive CD.
  • As such, the diagnosis is all too often delayed, typically detected at a late stage, and with a poor prognosis.
  • CD has become a well-recognized risk factor for the development of small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Crohn Disease / complications. Ileal Neoplasms / epidemiology. Jejunal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275076.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


91. Ulrich U, Rhiem K, Kaminski M, Wardelmann E, Trog D, Valter M, Richter ON: Parametrial and rectovaginal adenocarcinoma arising from endometriosis. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parametrial and rectovaginal adenocarcinoma arising from endometriosis.
  • Malignant extragonadal tumors arising from endometriosis are rare.
  • A 41-year-old gravida 1, para 1 (G1P1), with adenocarcinoma of the right parametrium arising from endometriosis and a 51-year-old G1P1 with endometriosis-associated rectovaginal adenocarcinoma were treated.
  • While the former patient was doing well 2 years after the primary diagnosis, the latter suffered a local pelvic recurrence 2 years later.
  • The analysis of PTEN in various forms of endometriosis and its malignant transformation may help in understanding the early steps of tumorigenesis.
  • [MeSH-major] Adenocarcinoma / etiology. Endometriosis / complications. Pelvic Neoplasms / etiology. Rectal Neoplasms / etiology. Vaginal Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cell Transformation, Neoplastic. Colectomy. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. PTEN Phosphohydrolase / genetics. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343215.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


92. Bergmann F, Aulmann S, Wente MN, Penzel R, Esposito I, Kleeff J, Friess H, Schirmacher P: Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol; 2006 Jun;59(6):580-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40.
  • BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) rarely affects people under 40.
  • [MeSH-minor] Adult. Age Factors. DNA Mutational Analysis / methods. DNA, Neoplasm / genetics. Female. Genes, ras. Humans. Mutation, Missense. Neoplasm Proteins / genetics


93. Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, Karsten T, Eilers PH, Tollenaar RA, van Wezel T, Morreau H: Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res; 2008 Feb 1;14(3):772-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Adequate preoperative staging of large sessile rectal tumors requires identifying adenomas that already contain an invasive focus, specifically those that are growing in or beyond the submucosa.
  • We systematically compared chromosomal instability patterns in adenoma and carcinoma fractions of the same lesion to assess specific steps in rectal tumor progression.
  • Both the adenoma and carcinoma fractions were typed with single nucleotide polymorphism arrays and compared with 21 previously described pure adenomas.
  • RESULTS: Five specific "malignant" events (gain of 8q, 13q, and 20q and loss of 17p and 18q) and aberrant staining for p53 and SMAD4 were all increased in the adenoma fractions of carcinoma cases compared with pure adenomas.
  • Paired analysis revealed that 31% of the samples had an equal amount of malignant aberrations in their adenoma and carcinoma fractions, whereas 25% had one and 33% had two or more extra malignant events in the carcinoma fraction.
  • However, the number of malignant aberrations in the biopsy with the most aberrations per tumor correlated with the corresponding adenoma or carcinoma fraction (r = 0.807; P < 0.001).
  • CONCLUSION: Five specific chromosomal aberrations, combined with immunohistochemistry for p53 and SMAD4, can predict possible progression of sessile rectal adenomas to early rectal cancer and can, after validation studies, be added to preoperative staging.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Adenoma / surgery. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / pathology. Carcinoma / surgery. Chromosomal Instability. Chromosome Aberrations. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245538.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


94. Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A, Skaar T, Mukherjee P: MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol; 2008 Sep 1;181(5):3116-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
  • MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma.
  • Significant enhancement in the development of pancreatic intraepithelial preneoplastic lesions and progression to adenocarcinoma is observed in PDA.MUC1 mice, possibly due to increased proliferation.
  • Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses.
  • [MeSH-major] Adenocarcinoma. Immune Tolerance. Mucin-1 / physiology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Cyclooxygenase 2 / genetics. Disease Progression. Humans. Indoleamine-Pyrrole 2,3,-Dioxygenase / genetics. Mice. Mice, Transgenic. Models, Animal. Tumor Escape. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Mol Med. 2004 Jan;10(1):15-8 [14720581.001]
  • [Cites] Breast Cancer Res. 2006;8(6):R69 [17156488.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):456-62 [15113850.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7341-9 [15187110.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5739-47 [15221004.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1045-50 [15154007.001]
  • [Cites] Nat Rev Immunol. 2004 Oct;4(10):762-74 [15459668.001]
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):1042-55 [15473694.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159-63 [2674949.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):157-70 [16965854.001]
  • [Cites] Clin Exp Immunol. 2007 Jun;148(3):419-24 [17362267.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2908-16 [1709586.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2457-9 [8495404.001]
  • [Cites] J Immunol. 1993 Aug 1;151(3):1654-62 [8393050.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3693-703 [7690810.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] J Biol Chem. 1995 Dec 15;270(50):30093-101 [8530414.001]
  • [Cites] Surg Today. 1995;25(11):954-8 [8640020.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):315-21 [9443411.001]
  • [Cites] Int J Biol Markers. 1998 Apr-Jun;13(2):51-69 [9803353.001]
  • [Cites] Clin Chem. 1999 May;45(5):630-7 [10222349.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Int J Cancer. 1999 Aug 27;82(5):721-6 [10417771.001]
  • [Cites] J Leukoc Biol. 2005 Jan;77(1):90-9 [15513966.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7764-72 [15944279.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1628-35 [16034102.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10079-87 [16267034.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):38-52 [16139507.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3586-94 [16319059.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):382-6 [16467169.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):186-97 [16628655.001]
  • [Cites] Mol Cancer Res. 2006 Jul;4(7):489-97 [16849524.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):613-25 [16862192.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2391-402 [16888001.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6A):4047-53 [17195456.001]
  • [Cites] J Immunol. 2000 Sep 15;165(6):3451-60 [10975866.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3730-41 [11034378.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):848s-855s [11300482.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):339-53 [11547902.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):128-34 [12185368.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44147-54 [12215436.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):97-100 [12455059.001]
  • [Cites] J Immunother. 2003 Jan-Feb;26(1):47-62 [12514429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2736-41 [12598658.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1269-74 [14502282.001]
  • [Cites] J Exp Ther Oncol. 2003 Nov-Dec;3(6):336-45 [14678522.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):365-71 [14681945.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] J Gastroenterol. 2003;38(12):1162-6 [14714254.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R37 [16846534.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • (PMID = 18713982.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / R01 CA118944; United States / NCI NIH HHS / CA / R01 CA118944; United States / NCI NIH HHS / CA / R01 CA118944-01A1; United States / NCI NIH HHS / CA / R01 CA118944-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 0 / MUC1 protein, human; 0 / Mucin-1; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ NIHMS57361; NLM/ PMC2625292
  •  go-up   go-down


95. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC: Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol; 2005 Sep;29(9):1125-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.
  • This study measured HER-2 overexpression in pancreatic adenocarcinoma at the genetic, transcriptional, and translational level.
  • Pancreatic adenocarcinoma samples (n = 30) were analyzed with immunohistochemical labeling for HER-2 protein, Quantitative real-time reverse transcriptase polymerase chain reaction (Q-RT-PCR) measurement of HER-2 mRNA and fluorescence in situ hybridization (FISH) analysis of HER-2 gene expression.
  • Five (17%) of the pancreatic adenocarcinomas scored maximal 3+ immunohistochemistry (IHC) labeling, seven (23%) had significantly increased expression of HER-2 mRNA, while only one (3%) exhibited low level HER-2 gene amplification.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Biomarkers, Tumor / analysis. Female. Gene Amplification. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096400.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


96. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C, Troupis TG, Salmas M, Kyroudis A, Kittas C, Gorgoulis VG: E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol; 2008 May;61(5):601-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus.
  • BACKGROUND: E2F-1 expression is positively associated with tumour growth in oesophageal squamous-cell carcinomas (OSCC), while it exhibits oncosuppressive features in colonic adenocarcinomas (AC).
  • To date there are no data regarding E2F-1 expression and its relationship with tumour kinetics (proliferation, apoptosis) in adenocarcinomas that develop on Barrett oesophagus.
  • AIM: As oesophageal adenocarcinomas occur almost exclusively in the metaplastic Barrett epithelium and the opposing E2F-1 behaviour seems to be cell and tissue-type dependent, we examined the manner in which E2F-1 acts in ACs of Barrett oesophagus.
  • These findings are opposite from those seen in OSCCs, suggesting that the tumour-suppressing E2F-1 behaviour in oesophageal adenocarcinomas is possibly due to the intestinal-type nature of the metaplastic Barrett mucosa.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Biomarkers, Tumor / metabolism. E2F1 Transcription Factor / metabolism. Esophageal Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Cell Proliferation. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908803.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


97. Kaynak K, Kara M, Oz B, Akgoz B, Sar M, Raz A: Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas. Acta Chir Belg; 2005 Aug;105(4):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas.
  • BACKGROUND: Pulmonary adenocarcinomas constitute a different histological subtype among the histological subtypes of non small cell lung carcinomas by showing comparably unfavourable rates of prognosis and different immunobiological features.
  • We conducted an immunohistochemical study to investigate AMFR expression in pulmonary adenocarcinomas and its effect on survival.
  • MATERIAL AND METHODS: We assessed AMFR expression using a monoclonal antibody (3F3A) in a total of 32 surgical specimens with stage I pulmonary adenocarcinomas that underwent curative resection.
  • CONCLUSIONS: AMFR expression predicts an unfavourable surgical outcome in patients with stage I pulmonary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Lung Neoplasms / metabolism. Lung Neoplasms / mortality. Receptors, Cytokine / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184720.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Receptors, Cytokine; EC 6.3.2.19 / AMFR protein, human; EC 6.3.2.19 / Receptors, Autocrine Motility Factor; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


98. Mortara L, Giuliani L, De Lerma Barbaro A, Accolla RS, Noonan DM: Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. Surg Oncol; 2007 Dec;16 Suppl 1:S33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.
  • We have previously shown that TS/A murine mammary adenocarcinoma cells, induced to express high surface expression of MHC class II molecules by stable transfection of CIITA, resulted in high rate (92%) of tumor rejection and tumor immunity to subsequent homologous tumor challenges.
  • [MeSH-major] Adenocarcinoma / immunology. Mammary Neoplasms, Animal / immunology. Nuclear Proteins / immunology. Trans-Activators / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035537.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / MHC class II transactivator protein; 0 / Nuclear Proteins; 0 / Trans-Activators; 187348-17-0 / Interleukin-12
  • [Number-of-references] 21
  •  go-up   go-down


99. Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX: Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol; 2007 Mar;33(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
  • AIMS: We aimed to investigate the sources of estrogen receptor alpha (ERalpha), estrogen receptor beta (ERbeta) and estimate the value of both ER subtypes in gastric adenocarcinoma and analyze the possible relationship of prothymosin alpha (ProTalpha) to ERs.
  • METHODS: ERs at the mRNA and protein levels in matched advanced gastric adenocarcinomas and surrounding non-cancerous tissues were examined by using reverse transcription-polymerase chain reaction and immunohistochemical (IHC) methods.
  • ERalpha immunoreactivity was only detected in poorly differentiated adenocarcinoma and ERalpha positive expression correlated with depth of invasion of the tumors.
  • Altered ERbeta in gastric adenocarcinoma correlated with decreased differentiation.
  • CONCLUSIONS: Altered expression of ERalpha and ERbeta in tumors compared with corresponding normal gastric tissues was more common in poorly differentiated adenocarcinomas and related to malignant properties, such as lymph node metastasis.
  • Decreased ERbeta and increased ProTalpha expression in advanced gastric adenocarcinoma indicated that ERbeta may play an anti-proliferation role which is opposed to the role of ProTalpha in gastric epithelium.
  • [MeSH-major] Adenocarcinoma. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Gene Expression Regulation, Neoplastic. Protein Precursors / genetics. RNA, Neoplasm / genetics. Stomach Neoplasms. Thymosin / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Differentiation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046193.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Protein Precursors; 0 / RNA, Neoplasm; 0 / prothymosin alpha; 61512-21-8 / Thymosin
  •  go-up   go-down


100. Al-Wadei HA, Schuller HM: beta-Carotene promotes the development of NNK-induced small airway-derived lung adenocarcinoma. Eur J Cancer; 2009 May;45(7):1257-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] beta-Carotene promotes the development of NNK-induced small airway-derived lung adenocarcinoma.
  • Here, we have tested the hypothesis that beta-carotene promotes the development of pulmonary adenocarcinoma (PAC) in vivo via cAMP signalling.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1370-80 [16206275.001]
  • [Cites] Mol Biol Cell. 2006 Feb;17(2):566-75 [16280361.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):403-11 [17067750.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1164-73 [17315157.001]
  • [Cites] Dermatol Clin. 2007 Oct;25(4):525-30, viii [17903611.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9572-80 [10734107.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Nov;126(11):624-30 [11079726.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2002 Mar;29(3):181-8 [11906480.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):537-43 [12094240.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1467-72 [15138589.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):11-8 [15196729.001]
  • [Cites] J Natl Cancer Inst. 1972 Mar;48(3):743-61 [5058973.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):963-71 [15880414.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):35-45 [15949588.001]
  • [Cites] Nature. 1974 Jul 5;250(461):64-6 [4841587.001]
  • [Cites] Biochim Biophys Acta. 2005 May 30;1740(2):179-88 [15949685.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1400-3 [10197601.001]
  • [Cites] Int Rev Exp Pathol. 1979;20:211-81 [536138.001]
  • [Cites] Exp Lung Res. 1980 Jun;1(2):171-80 [7227344.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):847-57 [6191989.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1960-5 [2306745.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(4):231-42 [1980173.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3164-73 [1591728.001]
  • [Cites] Carcinogenesis. 1993 Mar;14(3):451-5 [8453721.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 1;85(23):1906-16 [8230280.001]
  • [Cites] N Engl J Med. 1994 Apr 14;330(15):1029-35 [8127329.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1150-5 [8602180.001]
  • [Cites] Am J Ind Med. 1997 Dec;32(6):582-91 [9358913.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):60-6 [9890171.001]
  • (PMID = 19254833.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096128-03; United States / NCI NIH HHS / CA / R01 CA096128; United States / NCI NIH HHS / CA / R01 CA096128-03; United States / NCI NIH HHS / CA / R01CA096128
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / Nitrosamines; 0 / Retinoids; 01YAE03M7J / beta Carotene; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; E0399OZS9N / Cyclic AMP; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS116479; NLM/ PMC2694439
  •  go-up   go-down






Advertisement